U.S. patent application number 12/724750 was filed with the patent office on 2010-07-08 for phosphodiesterase 4 inhibitors.
Invention is credited to Elizabeth Doorly Graham, Allen T. Hopper, Richard A. Schumacher, Ashok Tehim.
Application Number | 20100173942 12/724750 |
Document ID | / |
Family ID | 32326501 |
Filed Date | 2010-07-08 |
United States Patent
Application |
20100173942 |
Kind Code |
A1 |
Schumacher; Richard A. ; et
al. |
July 8, 2010 |
PHOSPHODIESTERASE 4 INHIBITORS
Abstract
PDE4 inhibition is achieved by novel nitroxide compounds, e.g.,
N-substituted aniline and diphenylamine analogs. The compounds of
the present invention are of Formulas I-III: ##STR00001## wherein
A, B, D, R.sup.1, R.sup.2, R.sup.3, R.sup.7, R.sup.8, R.sup.9,
R.sup.10 and R.sup.6 are as defined herein.
Inventors: |
Schumacher; Richard A.;
(Monroe, NY) ; Graham; Elizabeth Doorly; (River
Vale, NJ) ; Hopper; Allen T.; (Glen Rock, NJ)
; Tehim; Ashok; (Ridgewood, NJ) |
Correspondence
Address: |
MILLEN, WHITE, ZELANO & BRANIGAN, PC
2200 CLARENDON BLVD, SUITE 1400
ARLINGTON
VA
22201
US
|
Family ID: |
32326501 |
Appl. No.: |
12/724750 |
Filed: |
March 16, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11378615 |
Mar 20, 2006 |
7700631 |
|
|
12724750 |
|
|
|
|
10715819 |
Nov 19, 2003 |
7087625 |
|
|
11378615 |
|
|
|
|
60427221 |
Nov 19, 2002 |
|
|
|
Current U.S.
Class: |
514/332 ;
514/340; 514/357 |
Current CPC
Class: |
A61P 21/00 20180101;
C07D 405/12 20130101; A61P 17/06 20180101; A61P 11/00 20180101;
A61P 25/24 20180101; C07D 401/06 20130101; A61P 35/04 20180101;
A61P 37/08 20180101; A61P 37/00 20180101; A61P 17/00 20180101; A61P
25/00 20180101; A61P 29/00 20180101; A61P 43/00 20180101; A61P 9/10
20180101; A61P 11/06 20180101; A61P 25/18 20180101; A61P 25/16
20180101; A61P 19/10 20180101; A61P 19/02 20180101; A61P 25/28
20180101; A61P 25/14 20180101; C07D 401/12 20130101; A61P 9/00
20180101; A61P 13/12 20180101; C07D 213/89 20130101; A61P 1/00
20180101 |
Class at
Publication: |
514/332 ;
514/357; 514/340 |
International
Class: |
A61K 31/444 20060101
A61K031/444; A61K 31/44 20060101 A61K031/44; A61P 19/10 20060101
A61P019/10; A61P 9/00 20060101 A61P009/00; A61P 19/02 20060101
A61P019/02; A61P 1/00 20060101 A61P001/00; A61P 25/00 20060101
A61P025/00; A61K 31/4439 20060101 A61K031/4439 |
Claims
1-84. (canceled)
85. A method for preventing or ameliorating osteoporosis in a
patient, for treating cardiovascular disease in a patient, for
treating rheumatoid arthritis in a patient, for treating B cell
chronic lymphocytic leukemia in a patient, for preventing or
treating colitis in a patient, or for treating a patient suffering
from a polyglutamine-repeat disease, said method comprising
administering to said patient an effective amount of a compound of
Formulas Nth ##STR00009## wherein one of A, B and D is N--O and the
others are CR.sup.6; R.sup.1 is alkyl having 1 to 4 carbon atoms,
which is branched or unbranched and which is unsubstituted or
substituted one or more times by halogen; R.sup.2 is alkyl having 1
to 12 carbon atoms which is branched or unbranched and which is
unsubstituted or substituted one or more times by halogen, hydroxy,
cyano, C.sub.1-4-alkoxy, oxo or combinations thereof, and wherein
optionally one or more --CH.sub.2CH.sub.2-- groups is replaced in
each case by --CH.dbd.CH-- or --C.ident.C--, cycloalkyl having 3 to
10 carbon atoms which is unsubstituted or substituted one or more
times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon
atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof,
cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted
or substituted in the cycloalkyl portion and/or the alkyl portion
one or more times by halogen, oxo, cyano, hydroxy, C.sub.1-4-alkyl,
C.sub.1-4-alkoxy or combinations thereof, aryl having 6 to 14
carbon atoms, which is unsubstituted or substituted one or more
times by halogen, CF.sub.3, OCF.sub.3, alkyl, hydroxy, alkoxy,
nitro, methylenedioxy, ethylenedioxy, cyano, or combinations
thereof, arylalkyl in which the aryl portion has 6 to 14 carbon
atoms and the alkyl portion, which is branched or unbranched, has 1
to 5 carbon atoms, wherein the arylalkyl radical is unsubstituted
or is substituted in the aryl portion one or more times by halogen,
CF.sub.3, OCF.sub.3, alkyl, hydroxy, alkoxy, nitro, cyano,
methylenedioxy, ethylenedioxy, or combinations thereof, and wherein
in the alkyl portion one or more --CH.sub.2CH.sub.2-- groups are
each optionally replaced by --CH.dbd.CH-- or --C.ident.C--, and/or
one or more --CH.sub.2-- groups are each optionally replaced by
--O-- or --NH-- and/or the alkyl portion is optionally substituted
by halogen, oxo, hydroxy, cyano, or combinations thereof, a
partially unsaturated carbocyclic group having 5 to 14 carbon
atoms, which is unsubstituted or substituted one or more times by
halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or combinations
thereof, a heterocyclic group, which is saturated, partially
saturated or unsaturated, having 5 to 10 ring atoms in which at
least 1 ring atom is an N, O or S atom, wherein the heterocyclic
group is unsubstituted or substituted one or more times by halogen,
hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo,
or combinations thereof, or a heterocycle-alkyl group, wherein the
heterocyclic portion is saturated, partially saturated or
unsaturated, and has 5 to 10 ring atoms in which at least 1 ring
atom is an N, O or S atom, and the alkyl portion is branched or
unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group
is unsubstituted or substituted one or more times in the
heterocyclic portion by halogen, OCF.sub.3, hydroxy, aryl, alkyl,
alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations
thereof, wherein in the alkyl portion one or more
--CH.sub.2CH.sub.2-- groups are each optionally replaced by
--CH.dbd.CH-- or --C.ident.C--, and/or one or more --CH.sub.2--
groups are each optionally replaced by --O-- or --NH-- and/or the
alkyl portion is optionally substituted by halogen, oxo, hydroxy,
cyano, or combinations thereof; R.sup.3 is H, cycloalkyl having 3
to 10 carbon atoms which is unsubstituted or substituted one or
more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4
carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations
thereof, aryl having 6 to 14 carbon atoms and which is
unsubstituted or substituted one or more times by halogen, alkyl,
alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro,
methylenedioxy, ethylenedioxy, trifluoromethyl, OCF.sub.3, amino,
aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic
acid, pyrrolyl, tetrazole-5-yl, 2(-heterocycle)tetrazole-5-yl,
hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano, acyl, alkylthio,
alkylsulfinyl, alkylsulfonyl, phenoxy, trialkylsilyloxy,
R.sup.4-L-, or combinations thereof, heteroaryl having 5 to 10 ring
atoms in which at least 1 ring atom is a heteroatom, which is
unsubstituted or substituted one or more times by halogen, alkyl,
hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy,
ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl,
aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic acid,
tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano,
acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy,
trialkylsilyloxy , R.sup.4-L-, or combinations thereof, or a
heterocyclic group, which is saturated, partially saturated or
unsaturated, having 5 to 10 ring atoms in which at least 1 ring
atom is an N, O or S atom, which is unsubstituted or substituted
one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano,
trifluoromethyl, nitro, oxo, or combinations thereof; R.sup.4 is H,
alkyl having 1 to 8 carbon atoms which is unsubstituted or
substituted one or more times by halogen, C.sub.1-4-alkyl,
C.sub.1-4-alkoxy, oxo, or combinations thereof, alkylamino or
dialkylamino wherein each alkyl portion has independently 1 to 8
carbon atom, a partially unsaturated carbocycle-alkyl group wherein
the carbocyclic portion has 5 to 14 carbon atoms and the alkyl
portion has 1 to 5 carbon atoms, which is unsubstituted or
substituted one or more times by halogen, alkyl, alkoxy, nitro,
cyano, oxo, or combinations thereof, cycloalkyl having 3 to 10
carbon atoms which is unsubstituted or substituted one or more
times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4
carbon atoms, or combinations thereof, cycloalkylalkyl having 4 to
16 carbon atoms which is unsubstituted or substituted in the
cycloalkyl portion and/or the alkyl portion one or more times by
halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations
thereof, aryl having 6 to 14 carbon atoms and which is
unsubstituted or substituted one or more times by halogen, alkyl,
hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy,
ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl,
aminoalkoxy, dialkylamino, hydroxyalkyl, hydroxamic acid,
tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl, cyano,
acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, cycloalkyl,
aryl, heteroaryl, or combinations thereof, arylalkyl having 7 to 19
carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and
the alkyl portion, which is branched or unbranched, has 1 to 5
carbon atoms, wherein the arylalkyl radical is unsubstituted or
substituted, in the aryl portion, one or more times by halogen,
trifluoromethyl, CF.sub.3O, nitro, amino, alkyl, alkoxy, amino,
alkylamino, dialkylamino, or combinations thereof, and/or
substituted in the alkyl portion by halogen, cyano, methyl, or
combinations thereof, wherein in the alkyl portion one or more
--CH.sub.2CH.sub.2-- groups are each optionally replaced by
--CH.dbd.CH-- or --C.ident.C--, and/or one or more --CH.sub.2--
groups are each optionally replaced by --O-- or --NH--, a
heterocyclic group, which is saturated, partially saturated or
unsaturated, having 5 to 10 ring atoms in which at least 1 ring
atom is an N, O or S atom, which is unsubstituted or substituted
one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy,
nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino,
aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl,
hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy,
alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl,
alkylsulfonyl, phenoxy, or combinations thereof, or a
heterocycle-alkyl group, wherein the heterocyclic portion is
saturated, partially saturated or unsaturated, and has 5 to 10 ring
atoms in which at least 1 ring atom is a N, O or S atom, and the
alkyl portion which is branched or unbranched and has 1 to 5 carbon
atoms, the heterocycle-alkyl group is unsubstituted or substituted
one or more times in the heterocyclic portion by halogen, alkyl,
alkoxy, cyano, trifluoromethyl, CFA), nitro, oxo, amino,
alkylamino, dialkylamino, or combinations thereof and/or
substituted in the alkyl portion by halogen, cyano, or methyl or
combinations thereof; L is a single bond or a divalent aliphatic
radical having 1 to 8 carbon atoms wherein one or more --CH.sub.2--
groups are each optionally replaced by --O--, --S--, --SO--,
--SO.sub.2--, --NR.sup.5--, --SO.sub.2NH--, --NHSO.sub.2--,
--SO.sub.2NR.sup.5--, --NR.sup.5SO.sub.2--, --CO--, --NR.sup.5CO--,
--CONR.sup.5--, --NHCONH--, --OCONH, --NHCOO--, --SCONH--,
--SCSNH--, or --NHCSNH--; R.sup.5 is H, alkyl having 1 to 8 carbon
atoms, which is branched or unbranched and which is unsubstituted
or substituted one or more times by halogen, C.sub.1-4-alkyl,
C.sub.1-4-alkoxy, oxo, or combinations thereof, aryl having 6 to 14
carbon atoms and which is unsubstituted or substituted one or more
times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro,
methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl,
aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl, hydroxamic
acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl,
cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, or
combinations thereof, or arylalkyl having 7 to 19 carbon atoms,
wherein the aryl portion has 6 to 14 carbon atoms and the alkyl
portion, which is branched or unbranched, has 1 to 5 carbon atoms,
wherein the arylalkyl radical is unsubstituted or substituted, in
the aryl portion, one or more times by halogen, trifluoromethyl,
CF.sub.3O, nitro, amino, alkyl, alkoxy, amino, alkylamino,
dialkylamino, or combinations thereof, and/or substituted in the
alkyl portion by halogen, cyano, methyl, or combinations thereof,
wherein in the alkyl portion one or more --CH.sub.2CH.sub.2--
groups are each optionally replaced by --CH.dbd.CH-- or
--C.ident.C--, and/or one or more --CH.sub.2-- groups are each
optionally replaced by --O-- or --NH--; R.sup.6 is H, halogen,
alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon
atoms, CN, or hydroxyl; R.sup.7 is H, alkyl having 1 to 8 carbon
atoms, which is branched or unbranched and which is unsubstituted
or substituted one or more times by halogen, cyano, hydroxy,
C.sub.1-4-alkoxy, or combinations thereof cycloalkyl having 3 to 10
carbon atoms which is unsubstituted or substituted one or more
times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon
atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof,
cycloalkylalkyl having 4 to 16 carbon atoms which is unsubstituted
or substituted in the cycloalkyl portion and/or the alkyl portion
one or more times by halogen, oxo, cyano, hydroxy, C.sub.1-4-alkyl,
C.sub.1-4-alkoxy or combinations thereof, aryl having 6 to 14
carbon atoms, which is unsubstituted or substituted one or more
times by halogen, CF.sub.3, OCF.sub.3, alkyl, hydroxy, alkoxy,
nitro, methylenedioxy, ethylenedioxy, cyano, or combinations
thereof, arylalkyl in which the aryl portion has 6 to 14 carbon
atoms and the alkyl portion, which is branched or unbranched, has 1
to 5 carbon atoms, wherein the arylalkyl radical is unsubstituted
or is substituted in the aryl portion one or more times by halogen,
CF.sub.3, OCF.sub.3, alkyl, hydroxy, alkoxy, nitro, cyano,
methylenedioxy, ethylenedioxy, or combinations thereof, and wherein
in the alkyl portion one or more --CH.sub.2CH.sub.2-- groups are
each optionally replaced by --CH.dbd.CH-- or --C.ident.C--, and/or
one or more --CH.sub.2-- groups are each optionally replaced by
--O-- or --NH-- and/or the alkyl portion is optionally substituted
by halogen, oxo, hydroxy, cyano, or combinations thereof, a
heterocyclic group, which is saturated, partially saturated or
unsaturated, having 5 to 10 ring atoms in which at least 1 ring
atom is an N, O or S atom, which is unsubstituted or substituted
one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy,
nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino,
aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl,
hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy,
alkoxycarbonyl, cyano, acyl, alkylthio, alkylsulfinyl,
alkylsulfonyl, phenoxy, or combinations thereof, or a
heterocycle-alkyl group, wherein the heterocyclic portion is
saturated, partially saturated or unsaturated, and has 5 to 10 ring
atoms in which at least 1 ring atom is a N, O or S atom, and the
alkyl portion which is branched or unbranched and has 1 to 5 carbon
atoms, the heterocycle-alkyl group is unsubstituted or substituted
one or more times in the heterocyclic portion by halogen, alkyl,
alkoxy, cyano, trifluoromethyl, CF.sub.3O, nitro, oxo, amino,
alkylamino, dialkylamino, or combinations thereof and/or
substituted in the alkyl portion by halogen, cyano, or methyl or
combinations thereof; R.sup.8 is H, or alkyl having 1 to 4 carbon
atoms, which is branched or unbranched and which is unsubstituted
or substituted one or more times by halogen, cyano, and/or
C.sub.1-4-alkoxy, and one or more --CH.sub.2CH.sub.2-- groups can
be replaced in each case by --CH.dbd.CH-- or --C.ident.C--; R.sup.9
is alkoxy or alkylthio, in each case having 1 to 4 carbon atoms,
which is branched or unbranched and which is unsubstituted or
substituted one or more times by halogen; R.sup.10 is
--CO--C.sub.1-4-alkyl which is branched or unbranched and which is
unsubstituted or substituted one or more times by halogen, or is
##STR00010## R.sup.11 is H or alkyl having 1 to 4 carbon atoms,
which is branched or unbranched, and which is unsubstituted or
substituted one or more times by halogen; R.sup.12 is alkyl having
1 to 6 carbon atoms, which is branched or unbranched, and which is
unsubstituted or substituted one or more times by halogen; R.sup.13
is alkyl having 1 to 6 carbon atoms, which is branched or
unbranched, and which is unsubstituted or substituted one or more
times by halogen; X and Y are each independently O or S; and G is
alkylene having 2 to 7 carbon atoms which is unsubstituted or
substituted one or more times by halogen; or a pharmaceutically
acceptable salt thereof; wherein an optically active compound can
be in the form of one of its separate enantiomers or mixtures
thereof, including racemic mixtures.
86. A method according to claim 85, wherein said method provides
prevention or amelioration of osteoporosis in a patient.
87. A method according to claim 85, wherein said patient is
suffering from cardiovascular disease.
88. A method according to claim 85, wherein said patient is
suffering from rheumatoid arthritis.
89. A method according to claim 85, wherein said patient is
suffering from B cell chronic lymphocytic leukemia.
90. A method according to claim 85, wherein said method provides
prevention or treatment of colitis in a patient.
91. A method according to claim 85, wherein said patient is
suffering from a polyglutamine-repeat disease.
92. A method according to claim 91, wherein said patient is
suffering from Huntington's disease.
93. A method according to claim 85, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridy-
lmethyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
94. A method according to claim 86, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridy-
lmethyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
95. A method according to claim 87, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
96. A method according to claim 88, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
97. A method according to claim 89, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
98. A method according to claim 90, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine, p1
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
99. A method according to claim 91, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline, 4-(2,4-Difluorophenyl)
sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-
-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
100. A method according to claim 92, wherein said compound is
selected from:
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphe-
nylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofur-
yloxy)diphenylamine,
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine,
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)di-
phenylamine,
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine,
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine,
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)--
4-aminobenzoic acid,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid,
N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridy-
lmethyl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid,
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid,
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid,
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid,
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridyl-
methyl)-3-aminobenzoic acid,
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid,
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine,
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine,
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine,
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine,
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine,
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine,
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine,
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine,
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine,
3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylm-
ethyl)diphenylamine,
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine,
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine,
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine,
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)-
diphenylamine,
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine,
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine,
3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline,
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline,
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline,
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline,
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-
-3-pyridylmethyl)aniline,
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobe-
nzofuran,
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl))aminobenzofuran,
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole,
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsul-
fonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline,
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(-
1-oxy-3-pyridylmethyl)-5-trifluoromethylbenzoic acid,
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid,
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid,
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid,
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-
-pyridylmethyl)benzoic acid,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid,
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid,
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid,
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4--
difluorophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid,
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline,
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline,
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid,
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)b-
enzoic acid,
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline,
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid,
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid,
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid,
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridy-
lmethyl)benzoic acid,
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[-
2-(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline,
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and pharmaceutically acceptable salts thereof,
wherein optically active compounds can be in the form of their
separate enantiomers or mixtures thereof, including racemic
mixtures.
Description
[0001] This application claims the benefit of priority of U.S.
provisional application No. 60/427,221, filed Nov. 19, 2002, the
entire disclosure of which is hereby incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates generally to the field of
phosphodiesterase 4 (PDE4) enzyme inhibition. More specifically
this invention relates to selective PDE4 inhibition by novel
compounds, e.g., pyridine N-oxide analogs of N-substituted
diarylamines, methods of preparing such compounds, compositions
containing such compounds, and methods of use thereof.
BACKGROUND OF THE INVENTION
[0003] The cyclic nucleotide specific phosphodiesterases (PDEs)
represent a family of enzymes that catalyze the hydrolysis of
various cyclic nucleoside monophosphates (including cAMP and cGMP).
These cyclic nucleotides act as second messengers within cells, and
as messengers, carry impulses from cell surface receptors having
bound various hormones and neurotransmitters. PDEs act to regulate
the level of cyclic nucleotides within cells and maintain cyclic
nucleotide homeostasis by degrading such cyclic mononucleotides
resulting in termination of their messenger role.
[0004] PDE enzymes can be grouped into eleven families according to
their specificity toward hydrolysis of cAMP or cGMP, their
sensitivity to regulation by calcium, calmodulin or cGMP, and their
selective inhibition by various compounds. For example, PDE 1 is
stimulated by Ca.sup.2+/calmodulin. PDE 2 is cGMP-dependent, and is
found in the heart and adrenals. PDE 3 is cGMP-dependent, and
inhibition of this enzyme creates positive inotropic activity. PDE
4 is cAMP specific, and its inhibition causes airway relaxation,
antiinflammatory and antidepressant activity. PDE 5 appears to be
important in regulating cGMP content in vascular smooth muscle, and
therefore PDE 5 inhibitors may have cardiovascular activity. Since
the PDEs possess distinct biochemical properties, it is likely that
they are subject to a variety of different forms of regulation.
[0005] PDE4 is distinguished by various kinetic properties
including low Michaelis constant for cAMP and sensitivity to
certain drugs. The PDE4 enzyme family consists of four genes, which
produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B,
PDE4C, and PDE4D [See: Wang et al., Expression, Purification, and
Characterization of human cAMP-Specific Phosphodiesterase (PDE4)
Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320-324
(1997)]. In addition, various splice variants of each PDE4 isoform
have been identified.
[0006] PDE4 isoenzymes are localized in the cytosol of cells and
are unassociated with any known membranous structures. PDE4
isoenzymes specifically inactivate cAMP by catalyzing its
hydrolysis to adenosine 5'-monophosphate (AMP). Regulation of cAMP
activity is important in many biological processes, including
inflammation and memory. Inhibitors of PDE4 isoenzymes such as
rolipram, piclamilast, CDP-840 and ariflo are powerful
antiinflammatory agents and therefore may be useful in treating
diseases where inflammation is problematic such as asthma or
arthritis. Further, rolipram improves the cognitive performance of
rats and mice in learning paradigms.
##STR00002##
[0007] In addition to such compounds as rolipram, xanthine
derivatives such as pentoxifyl]ine, denbufyl]ine, and theophyl]ine
inhibit PDE4 and have received considerable attention of late for
their cognition enhancing effects. cAMP and cGMP are second
messengers that mediate cellular responses to many different
hormones and neurotransmitters. Thus, therapeutically significant
effects may result from PDE inhibition and the resulting increase
in intracellular cAMP or cGMP in key cells, such as those located
in the nervous system and elsewhere in the body.
[0008] Rolipram, previously in development as an anti-depressant,
selectively inhibits the PDE4 enzyme and has become a standard
agent in the classification of PDE enzyme subtypes. Early work in
the PDE4 field focused on depression and inflammation, and has
subsequently been extended to include indications such as dementia.
[see "The PDE IV Family Of Calcium-Phosphodiesterases Enzymes,"
John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799-807
for a general review). Further clinical developments of rolipram
and other first-generation PDE4 inhibitors were terminated due to
the side effect profile of these compounds. The primary side effect
in primates is emesis, while the primary side effects in rodents
are testicular degranulation, weakening of vascular smooth muscle,
psychotrophic effects, increased gastric acid secretion and stomach
erosion.
SUMMARY OF THE INVENTION
[0009] The present invention relates to novel compounds, e.g.,
pyridine N-oxide analogs of N-substituted diarylamine compounds,
that inhibit PDE4 enzymes, and especially have improved side effect
profiles, e.g., are relatively non-emetic, (e.g., as compared to
the previously discussed prior art compounds). Preferably, the
compounds selectively inhibit PDE4 enzymes. The compounds of this
invention at the same time facilitate entry into cells, especially
cells of the nervous system.
[0010] Still further, the present invention provides methods for
synthesizing compounds with such activity and selectivity as well
as methods of (and corresponding pharmaceutical compositions for)
treating a patient, e.g., mammals, including humans, requiring PDE
inhibition, especially PDE4 inhibition, for a disease state that
involves elevated intracellular PDE 4 levels or decreased cAMP
levels, e.g., involving neurological syndromes, especially those
states associated with memory impairment, most especially long term
memory impairment, as where such memory impairment is due in part
to catabolism of intracellular cAMP levels by PDE 4 enzymes, or
where such memory impairment may be improved by effectively
inhibiting PDE4 enzyme activity.
[0011] In a preferred aspect, the compounds of the invention
improve such diseases by inhibiting PDE4 enzymes at doses which do
not induce emesis.
[0012] The present invention includes nitroxide compounds of
Formulas I-III:
##STR00003##
[0013] wherein
[0014] one of A, B and D is N--O and the others are CR.sup.6
(preferably, B is N--O) [0015] R.sup.1 is alkyl having 1 to 4
carbon atoms, which is branched or unbranched and which is
unsubstituted or substituted one or more times by halogen (e.g.,
CH.sub.3, CHF.sub.2, CF.sub.3, etc.); [0016] R.sup.2 is alkyl
having 1 to 12, preferably 1 to 8 carbon atoms, which is branched
or unbranched and which is unsubstituted or substituted one or more
times by halogen, hydroxy, cyano, C.sub.1-4-alkoxy, oxo or
combinations thereof, and wherein optionally one or more
--CH.sub.2CH.sub.2-- groups is replaced in each case by
--CH.dbd.CH-- or --C.ident.C-- (e.g., CH.sub.3, CHF.sub.2,
CF.sub.3, methoxyethyl, etc.), [0017] cycloalkyl having 3 to 10,
preferably 3 to 8 carbon atoms, which is unsubstituted or
substituted one or more times by halogen, hydroxy, oxo, cyano,
alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon
atoms, or combinations thereof (e.g., cyclopentyl), [0018]
cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms,
which is unsubstituted or substituted in the cycloalkyl portion
and/or the alkyl portion one or more times by halogen, oxo, cyano,
hydroxy, C.sub.1-4-alkyl, C.sub.1-4-alkoxy or combinations thereof
(e.g., cyclopentylmethyl, cyclopropylmethyl, etc.), [0019] aryl
having 6 to 14 carbon atoms, which is unsubstituted or substituted
one or more times by halogen, CF.sub.3, OCF.sub.3, alkyl, hydroxy,
alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or
combinations thereof (e.g., methylphenyl, methoxyphenyl,
chlorophenyl, etc.), [0020] arylalkyl in which the aryl portion has
6 to 14 carbon atoms and the alkyl portion, which is branched or
unbranched, has 1 to 5 carbon atoms, wherein the arylalkyl radical
is unsubstituted or is substituted in the aryl portion one or more
times by halogen, CF.sub.3, OCF.sub.3, alkyl, hydroxy, alkoxy,
nitro, cyano, methylenedioxy, ethylenedioxy, or combinations
thereof, and wherein in the alkyl portion one or more
--CH.sub.2CH.sub.2-- groups are each optionally replaced by
--CH.dbd.CH-- or --C.ident.C--, and/or one or more --CH.sub.2--
groups are each optionally replaced by --O-- or --NH-- and/or the
alkyl portion is optionally substituted by halogen, oxo, hydroxy,
cyano, or combinations thereof (e.g., phenylethyl, phenylpropyl,
phenylbutyl, methoxyphenylethyl, methoxyphenylpropyl,
chlorophenylethyl, chlorophenylpropyl, phenylethenyl, phenoxyethyl,
phenoxybutyl, chlorophenoxyethyl, chlorophenylaminoethyl, etc.),
[0021] a partially unsaturated carbocyclic group having 5 to 14
carbon atoms, which is unsubstituted or substituted one or more
times by halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or
combinations thereof (e.g., cyclohexenyl, cyclohexadienyl, indanyl,
tetrahydronaphthenyl, etc.), [0022] a heterocyclic group, which is
saturated, partially saturated or unsaturated, having 5 to 10 ring
atoms in which at least 1 ring atom is an N, O or S atom, wherein
the heterocyclic group is unsubstituted or substituted one or more
times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano,
trifluoromethyl, nitro, oxo, or combinations thereof (e.g.,
3-thienyl, 3-tetrahydrofuranyl, 3-pyrrolyl, etc.), or [0023] a
heterocycle-alkyl group, wherein the heterocyclic portion is
saturated, partially saturated or unsaturated, and has 5 to 10 ring
atoms in which at least 1 ring atom is an N, O or S atom, and the
alkyl portion is branched or unbranched and has 1 to 5 carbon
atoms, the heterocycle-alkyl group is unsubstituted or substituted
one or more times in the heterocyclic portion by halogen,
OCF.sub.3, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl,
nitro, oxo, or combinations thereof, wherein in the alkyl portion
one or more --CH.sub.2CH.sub.2-- groups are each optionally
replaced by --CH.dbd.CH-- or --CE C--, and/or one or more
--CH.sub.2-- groups are each optionally replaced by --O-- or --NH--
and/or the alkyl portion is optionally substituted by halogen, oxo,
hydroxy, cyano, or combinations thereof (e.g., pyridylethyl,
pydridylpropyl, methylpiperazinylethyl, etc.); [0024] R.sup.3 is H,
[0025] cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms,
which is unsubstituted or substituted one or more times by halogen,
hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy
having 1 to 4 carbon atoms, or combinations thereof (e.g.,
cyclopentyl), [0026] aryl having 6 to 14 carbon atoms and which is
unsubstituted or substituted one or more times by halogen, alkyl,
alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro,
methylenedioxy, ethylenedioxy, trifluoromethyl, OCF.sub.3, amino,
aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (e.g.,
hydroxymethyl), hydroxamic acid, pyrrolyl, tetrazole-5-yl,
2(-heterocycle)tetrazole-5-yl (e.g.,
2-(2-tetrahydropyranyl)tetrazole-5-yl), hydroxyalkoxy, carboxy,
alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl),
cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy,
trialkylsilyloxy (e.g. tert-butyldimethylsilyloxy), R.sup.4-L-, or
combinations thereof (e.g., substituted or unsubstituted phenyl,
naphthyl, and biphenyl, such as phenyl, methylphenyl, chlorophenyl,
fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl,
ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl,
dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl,
etc.), [0027] heteroaryl having 5 to 10 ring atoms in which at
least 1 ring atom is a heteroatom (preferably N, S or O), which is
unsubstituted or substituted one or more times by halogen, alkyl,
hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy,
ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl,
aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl),
hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy,
alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl),
cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy,
trialkylsilyloxy (e.g. tert-butyldimethylsilyloxy), R.sup.4-L-, or
combinations thereof (e.g., pyridyl, thienyl, pyrazinyl,
quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl,
etc.), or [0028] a heterocyclic group, which is saturated,
partially saturated or unsaturated, having 5 to 10 ring atoms in
which at least 1 ring atom is an N, O or S atom, which is
unsubstituted or substituted one or more times by halogen, hydroxy,
aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or
combinations thereof (e.g., 3-thienyl, 3-tetrahydrofuranyl,
3-pyrrolyl, etc.); [0029] R.sup.4 is H, [0030] alkyl having 1 to 8,
preferably 1 to 4 carbon atoms, which is unsubstituted or
substituted one or more times by halogen, C.sub.1-4-alkyl,
C.sub.1-4-alkoxy, oxo, or combinations thereof (e.g., methyl,
ethyl, propyl, etc.), [0031] alkylamino or dialkylamino wherein
each alkyl portion has independently 1 to 8, preferably 1 to 4
carbon atoms (e.g., dimethylamino, etc.), [0032] a partially
unsaturated carbocycle-alkyl group wherein the carbocyclic portion
has 5 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon
atoms, which is unsubstituted or substituted, preferably in the
carbocyclic portion, one or more times by halogen, alkyl, alkoxy,
nitro, cyano, oxo, or combinations thereof (e.g.,
cyclohexenylmethyl, etc.), [0033] cycloalkyl having 3 to 10,
preferably 3 to 8 carbon atoms, which is unsubstituted or
substituted one or more times by halogen, hydroxy, oxo, cyano,
alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof
(e.g., cyclopentyl), [0034] cycloalkylalkyl having 4 to 16,
preferably 4 to 12 carbon atoms, which is unsubstituted or
substituted in the cycloalkyl portion and/or the alkyl portion one
or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or
combinations thereof (e.g., cyclopentylmethyl, cyclopropylmethyl,
etc.), [0035] aryl having 6 to 14 carbon atoms and which is
unsubstituted or substituted one or more times by halogen, alkyl,
hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy,
ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl,
aminoalkoxy, dialkylamino, hydroxyalkyl (e.g., hydroxymethyl),
hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy,
alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl),
cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy,
cycloalkyl, aryl (e.g., phenyl, naphthyl, and biphenyl),
heteroaryl, or combinations thereof (e.g., substituted or
unsubstituted phenyl and naphthyl, methylphenyl, chlorophenyl,
fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl,
ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl,
dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl,
etc.), [0036] arylalkyl having 7 to 19 carbon atoms, wherein the
aryl portion has 6 to 14 carbon atoms and the alkyl portion, which
is branched or unbranched, has 1 to 5 carbon atoms, wherein the
arylalkyl radical is unsubstituted or substituted, in the aryl
portion, one or more times by halogen, trifluoromethyl, CF.sub.3O,
nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino, or
combinations thereof, and/or substituted in the alkyl portion by
halogen, cyano, methyl, or combinations thereof, wherein in the
alkyl portion one or more --CH.sub.2CH.sub.2-- groups are each
optionally replaced by --CH.dbd.CH-- or --CE C--, and/or one or
more --CH.sub.2-- groups are each optionally replaced by --O-- or
--NH-- (e.g., benzyl, phenethyl, phenpropyl, methylbenzyl,
methoxybenzyl, trfluoromethyl, benzyl, methylenedioxobenzyl, etc.),
[0037] a heterocyclic group, which is saturated, partially
saturated or unsaturated, having 5 to 10 ring atoms in which at
least 1 ring atom is an N, O or S atom, which is unsubstituted or
substituted one or more times by halogen, alkyl, hydroxy, alkoxy,
alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy,
trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy
dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid,
tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g.,
tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio,
alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof
(e.g., pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl,
pyrimidinyl, imidazolyl, thiazolyl, etc.), or [0038] a
heterocycle-alkyl group, wherein the heterocyclic portion is
saturated, partially saturated or unsaturated, and has 5 to 10 ring
atoms in which at least 1 ring atom is a N, O or S atom, and the
alkyl portion which is branched or unbranched and has 1 to 5 carbon
atoms, the heterocycle-alkyl group is unsubstituted or substituted
one or more times in the heterocyclic portion by halogen, alkyl,
alkoxy, cyano, trifluoromethyl, CF.sub.3O, nitro, oxo, amino,
alkylamino, dialkylamino, or combinations thereof and/or
substituted in the alkyl portion by halogen, cyano, or methyl or
combinations thereof (e.g., pyridylmethyl, pyridylpropyl,
methylpridylmethyl, etc.); [0039] L is a single bond or a divalent
aliphatic radical having 1 to 8 carbon atoms wherein one or more
--CH.sub.2-- groups are each optionally replaced by --O--, --S--,
--SO--, --SO.sub.2--, --NR.sup.5--, --SO.sub.2NH--, --NHSO.sub.2--,
--SO.sub.2NR.sup.5--, --NR.sup.5SO.sub.2--, --CO--, --NR.sup.5CO--,
--CONR.sup.5--, --NHCONH--, --OCONH, --NHCOO--, --SCONH--,
--SCSNH--, or --NHCSNH-- (e.g., --O--, CH.sub.2--, --CO--,
--CO--O--, --O--CO--, --CO--NH--, --NH--CO--,
--CH.sub.2CH.sub.2CH.sub.2--NH--CO--, --CH.sub.2--CH.sub.2--O--,
--SO.sub.2--NH--CH.sub.2CH.sub.2--O--, --O--CH.sub.2CH.sub.2--O--,
--CH.sub.2--NH--CO--, --CO--NH--CH.sub.2--, --SO.sub.2--NH--,
--CH.sub.2--NH--SO.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--SO.sub.2--NH--, --CO--NH--SO.sub.2--,
--SO.sub.2--, --SO.sub.2NHCO--, etc.); [0040] R.sup.5 is H, [0041]
alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is
branched or unbranched and which is unsubstituted or substituted
one or more times by halogen, C.sub.1-4-alkyl, C.sub.1-4-alkoxy,
oxo, or combinations thereof (e.g., methyl, ethyl, propyl, etc.),
[0042] aryl having 6 to 14 carbon atoms and which is unsubstituted
or substituted one or more times by halogen, alkyl, hydroxy,
alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy,
trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy
dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid,
tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g.,
tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio,
alkylsulfinyl, alkylsulfonyl, (e.g., substituted or unsubstituted
phenyl and naphthyl, methylphenyl, chlorophenyl, fluorophenyl,
vinylphenyl, cyanophenyl, methylenedioxophenyl, ethylphenyl,
dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl,
dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl,
etc.), or [0043] arylalkyl having 7 to 19 carbon atoms, wherein the
aryl portion has 6 to 14 carbon atoms and the alkyl portion, which
is branched or unbranched, has 1 to 5 carbon atoms, wherein the
arylalkyl radical is unsubstituted or substituted, in the aryl
portion, one or more times by halogen, trifluoromethyl, CF.sub.3O,
nitro, amino, alkyl, alkoxy, amino, alkylamino, dialkylamino, or
combinations thereof, and/or substituted in the alkyl portion by
halogen, cyano, methyl, or combinations thereof, wherein in the
alkyl portion one or more --CH.sub.2CH.sub.2-- groups are each
optionally replaced by --CH.dbd.CH-- or --CEC--, and/or one or more
--CH.sub.2-- groups are each optionally replaced by --O-- or --NH--
(e.g., benzyl, phenethyl, phenpropyl, methylbenzyl, methoxybenzyl,
trfluoromethyl, benzyl, methylenedioxobenzyl, etc.); [0044] R.sup.6
is H, halogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to
4 carbon atoms, CN, or hydroxyl; [0045] R.sup.7 is H, [0046] alkyl
having 1 to 8 carbon atoms, which is branched or unbranched and
which is unsubstituted or substituted one or more times by halogen,
cyano, hydroxy, C.sub.1-4-alkoxy, or combinations thereof [0047]
cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is
unsubstituted or substituted one or more times by halogen, hydroxy,
oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4
carbon atoms, or combinations thereof (e.g., cyclopentyl), [0048]
cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms,
which is unsubstituted or substituted in the cycloalkyl portion
and/or the alkyl portion one or more times by halogen, oxo, cyano,
hydroxy, C.sub.1-4-alkyl, C.sub.1-4-alkoxy or combinations thereof
(e.g., cyclopentylmethyl, cyclopropylmethyl, etc.), [0049] aryl
having 6 to 14 carbon atoms, which is unsubstituted or substituted
one or more times by halogen, CF.sub.3, OCF.sub.3, alkyl, hydroxy,
alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or
combinations thereof (e.g., methylphenyl, methoxyphenyl,
chlorophenyl, etc.), [0050] arylalkyl in which the aryl portion has
6 to 14 carbon atoms and the alkyl portion, which is branched or
unbranched, has 1 to 5 carbon atoms, wherein the arylalkyl radical
is unsubstituted or is substituted in the aryl portion one or more
times by halogen, CF
.sub.3, OCF.sub.3, alkyl, hydroxy, alkoxy, nitro, cyano,
methylenedioxy, ethylenedioxy, or combinations thereof, and wherein
in the alkyl portion one or more --CH.sub.2CH.sub.2-- groups are
each optionally replaced by --CH.dbd.CH-- or --CEC--, and/or one or
more --CH.sub.2-- groups are each optionally replaced by --O-- or
--NH-- and/or the alkyl portion is optionally substituted by
halogen, oxo, hydroxy, cyano, or combinations thereof (e.g.,
phenylethyl, phenylpropyl, phenylbutyl, methoxyphenylethyl,
methoxyphenylpropyl, chlorophenylethyl, chlorophenylpropyl,
phenylethenyl, phenoxyethyl, phenoxybutyl, chlorophenoxyethyl,
chlorophenylaminoethyl, etc.), [0051] a heterocyclic group, which
is saturated, partially saturated or unsaturated, having 5 to 10
ring atoms in which at least 1 ring atom is an N, O or S atom,
which is unsubstituted or substituted one or more times by halogen,
alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy,
ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl,
aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl),
hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy,
alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl),
cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or
combinations thereof (e.g., tetrahydrofuranyl, pyridyl, thienyl,
pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl,
thiazolyl, etc.), or [0052] a heterocycle-alkyl group, wherein the
heterocyclic portion is saturated, partially saturated or
unsaturated, and has 5 to 10 ring atoms in which at least 1 ring
atom is an N, O or S atom, and the alkyl portion is branched or
unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group
is unsubstituted or substituted one or more times in the
heterocyclic portion by halogen, OCF.sub.3, hydroxy, aryl, alkyl,
alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations
thereof, wherein in the alkyl portion one or more
--CH.sub.2CH.sub.2-- groups are each optionally replaced by
--CH.dbd.CH-- or --CE C--, and/or one or more --CH.sub.2-- groups
are each optionally replaced by --O-- or --NH-- and/or the alkyl
portion is optionally substituted by halogen, oxo, hydroxy, cyano,
or combinations thereof (e.g., pyridylethyl, pydridylpropyl,
methylpiperazinylethyl, etc.); [0053] R.sup.8 is H, or [0054] alkyl
having 1 to 4 carbon atoms, which is branched or unbranched and
which is unsubstituted or substituted one or more times by halogen,
cyano, and/or C.sub.1-4-alkoxy (e.g., CH.sub.3, C.sub.2H.sub.5,
CHF.sub.2, CF.sub.3, etc.), and one or more --CH.sub.2CH.sub.2--
groups can be replaced in each case by --CH.dbd.CH-- or
--C.ident.C--; [0055] R.sup.9 is alkoxy or alkylthio, in each case
having 1 to 4 carbon atoms, which is branched or unbranched and
which is unsubstituted or substituted one or more times by halogen
(e.g., OCH.sub.3, OCHF.sub.2, OCF.sub.3, etc.); [0056] R.sup.10 is
--CO--C.sub.1-4-alkyl which is branched or unbranched and which is
unsubstituted or substituted one or more times by halogen (e.g.,
CH.sub.3, CHF.sub.2, CF.sub.3, etc.), or is
[0056] ##STR00004## [0057] R.sup.11 is H or alkyl having 1 to 4
carbon atoms, which is branched or unbranched, and which is
unsubstituted or substituted one or more times by halogen (e.g.,
CH.sub.3, CHF.sub.2, CF.sub.3, etc.); [0058] R.sup.12 is alkyl
having 1 to 6 carbon atoms, which is branched or unbranched, and
which is unsubstituted or substituted one or more times by halogen
(e.g., CH.sub.3, CHF.sub.2, CF.sub.3, etc.); [0059] R.sup.13 is
alkyl having 1 to 6 carbon atoms, which is branched or unbranched,
and which is unsubstituted or substituted one or more times by
halogen (e.g., CH.sub.3, CHF.sub.2, CF.sub.3, etc.); [0060] X and Y
are each independently O or S; and [0061] G is alkylene having 2 to
7 carbon atoms which is unsubstituted or substituted one or more
times by halogen; and [0062] pharmaceutically acceptable salts
thereof; wherein optically active compounds can be in the form of
one of their separate enantiomers or in the form of mixtures
thereof, including racemic mixtures.
[0063] Corresponding compounds in which the N atom of the pyridyl
ring is not in nitroxide form are disclosed in related applications
Ser. No. 10/051,309, filed Jan. 22, 2002, Ser. No. 60/396,726,
filed Jul. 19, 2002, and Ser. No. 10/622,117, filed Jul. 18, 2003,
the entire disclosures of which are incorporated herein by
reference.
[0064] The compounds of the present invention are effective in
inhibiting, or modulating the activity of PDE4 in animals, e.g.,
mammals, especially humans. These compounds exhibit neurological
activity, especially where such activity affects cognition,
including long term memory. These compounds will also be effective
in treating diseases where decreased cAMP levels are involved. This
includes but is not limited to inflammatory diseases. These
compounds may also function as antidepressants, or be useful in
treating cognitive and negative symptoms of schizophrenia.
[0065] Assays for determining PDE inhibiting activity as well as
selectivity of PDE 4 inhibiting activity and selectivity of
inhibiting PDE 4 isoenzymes are known within the art. See, e.g.,
U.S. Pat. No. 6,136,821, the disclosure of which is incorporated
herein by reference.
[0066] According to a further aspect of the invention there are
provided compounds useful as intermediates for the production of
the PDE4 inhibitors described herein (e.g., PDE4 inhibitors of
Formulas I-III) and/or useful for the synthesis of radio-labeled
analogs of the PDE4 inhibitors with in this application.
[0067] Thus, there are provided intermediate compounds which
correspond to compounds of Formula I, wherein R.sup.2 and R.sup.3
are as previously defined for Formula I, but R.sup.1 is H,
tert-butyldimethylsilyl-, or a suitable phenolic protecting group.
Suitable phenolic protecting groups are described, for example, in
Greene, T.W. and Wuts, P. G. M., Protective Groups in Organic
Synthesis, 3.sup.rd Edition, John Wiley & Sons, 1999, pp.
246-293. These intermediates are also useful for the synthesis of
radio-labeled compounds, such as where R.sup.1 is .sup.3H.sub.3C--,
.sup.14CH.sub.3-- or .sup.11CH.sub.3--, for example by removing the
protecting group and reacting the resultant compound in which
R.sup.1 is H with suitable radio-labelled reagents. Such
radio-labeled compounds are useful for determining compound tissue
distribution in animals, in PET imaging studies, and for in vivo,
ex vivo, and in vitro binding studies.
[0068] Also provided are intermediate compounds which correspond to
compounds of Formula I, wherein R.sup.1 and R.sup.3 are as
previously defined for Formula I, but R.sup.2 is H,
tert-butyldimethylsilyloxy-, or a suitable phenolic protecting
group. Suitable phenolic protecting groups are described, for
example, in Greene, T. W. and Wuts, P. G. M., Protective Groups in
Organic Synthesis, 3.sup.rd Edition, John Wiley & Sons, 1999,
pp. 246-293. Compounds in which R.sup.2 is H are useful as
intermediates, for example, as scaffolds for parallel or
combinatorial chemistry applications. Further, these compounds are
useful for the introduction of radio-labels such as .sup.3H,
.sup.14C, or .sup.11C.
[0069] Other preferred intermediates are compounds that are in
accordance with any one of Formulas I-III, except that R.sup.3 is
H. Additional radio-labeled compounds that are useful for
determining compound tissue distribution in animals, in PET imaging
studies, and for in vivo, ex vivo, and in vitro binding studies are
compounds according to Formulas I-III wherein R.sup.3 is aryl and
the aryl structure contains a .sup.14C atom in the ring, as well as
compounds of Formula III in which R.sup.9 is OCH.sub.3 in which the
C atom is .sup.14C or at least one of the H atoms is .sup.3H.
[0070] Halogen herein refers to F, Cl, Br, and I. Preferred
halogens are F and Cl.
[0071] Alkyl, as a group or substituent per se or as part of a
group or substituent (e.g., alkylamino, trialkylsilyloxy,
aminoalkyl, hydroxyalkyl), means generally a straight-chain or
branched-chain aliphatic hydrocarbon radical having, for example, 1
to 12 carbon atoms, preferably 1 to 8 carbon atoms, especially 1 to
4 carbon atoms. Suitable alkyl groups include methyl, ethyl,
propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl,
heptyl, octyl, nonyl, decyl, undecyl, and dodecyl. Other examples
of suitable alkyl groups include 1-, 2-- or 3-methylbutyl, 1,1-,
1,2-- or 2,2-dimethylpropyl, 1-ethylpropyl, 1-, 2-, 3-- or
4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3-- or 3,3-dimethylbutyl,
1-- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl,
methylhexyl, dimethylpentyl, ethylpentyl, ethylmethylbutyl,
dimethylbutyl, and the like.
[0072] Substituted alkyl groups are alkyl groups as described above
which are substituted in one or more positions by, for example,
halogens, oxo, hydroxyl, C.sub.1-4-alkoxy and/or cyano. Halogens
are preferred substituents, especially F and Cl.
[0073] Alkoxy means alkyl-O-- groups and alkoxyalkoxy means
alkyl-O-alkyl-O-- groups in which the alkyl portions are in
accordance with the previous discussion. Suitable alkoxy and
alkoxyalkoxy groups include methoxy, ethoxy, propoxy, butoxy,
pentoxy, hexoxy, heptoxy, octoxy methoxymethoxy ethoxymethoxy,
propoxymethoxy, and methoxyethoxy. Preferred alkoxy groups are
methoxy and ethoxy. Similarly, alkoxycarbonyl means alkyl-O--CO--
in which the alkyl portion is in accordance with the previous
discussion. Examples include methoxycarbonyl, ethoxycarbonyl,
propoxycarbonyl, and tert-butoxycarbonyl.
[0074] Cycloalkyl means a monocyclic, bicyclic or tricyclic
nonaromatic saturated hydrocarbon radical having 3 to 10 carbon
atoms, preferably 3 to 8 carbon atoms, especially 3 to 6 carbon
atoms. Suitable cycloalkyl groups include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl,
1-decalin, adamant-1-yl, and adamant-2-yl. Other suitable
cycloalkyl groups include spiropentyl, bicyclo[2.1.0]pentyl,
bicyclo[3.1.0] hexyl, spiro [2.4]heptyl, spiro[2.5]octyl,
bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl,
spiro[3.3]heptyl, bicyclo[4.2.0]octyl, and spiro[3.5]nonyl.
Preferred cycloalklyl groups are cyclopropyl, cyclopentyl and
cyclohexyl. The cycloalkyl group can be substituted, for example,
substituted by halogens and/or alkyl groups.
[0075] Cycloalkylalkyl refers to cycloalkyl-alkyl radicals in which
the cycloalkyl and alkyl portions are in accordance with previous
discussions. Suitable examples include cyclopropylmethyl and
cyclopentylmethyl.
[0076] Aryl, as a group or substituent per se or as part of a group
or substituent, refers to an aromatic carbocyclic radical
containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms,
especially 6 to 10 carbon atoms. Suitable aryl groups include
phenyl, naphthyl and biphenyl. Substituted aryl groups include the
above-described aryl groups which are substituted one or more times
by, for example, halogen, alkyl, hydroxy, alkoxy, nitro,
methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino,
hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl,
alkylthio, alkylsulfinyl, alkylsulfonyl, and phenoxy.
[0077] Arylalkyl refers to an aryl-alkyl-radical in which the aryl
and alkyl portions are in accordance with the previous
descriptions. Suitable examples include benzyl, 1-phenethyl,
2-phenethyl, phenpropyl, phenbutyl, phenpentyl, and
napthylmethyl.
[0078] Heteroaryl refers to an aromatic heterocyclic group having
one or two rings and a total number of 5 to 10 ring atoms wherein
at least one of the ring atoms is a heteroatom. Preferably, the
heteroaryl group contains 1 to 3, especially 1 or 2, hetero-ring
atoms which are selected from N, O and S. Suitable heteroaryl
groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl,
triazolyl, tetrazolyl, dithialyl, oxathialyl, isoxazolyl, oxazolyl,
thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl,
oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl,
pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl,
oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl,
isothionaphthenyl, indolyl, isoindolyl, indazolyl, benzisoxazolyl,
benzoxazolyl, benzthiazolyl, benzisothiazolyl, purinyl,
benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl,
naphthyridinyl, and benzoxazinyl, e.g., 2-thienyl, 3-thienyl, 2-,
3-- or 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-- or 8-quinolinyl, and 1-,
3-, 4-, 5-, 6-, 7-- or 8-isoquinolinyl.
[0079] Substituted heteroaryl refers to the heteroaryl groups
described above which are substitued in one or more places by, for
example, halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano,
trifluoromethyl, nitro, oxo, amino, alkylamino, and
dialkylamino.
[0080] Heterocycles include heteroaryl groups as described above as
well as non-aromatic cyclic groups containing at least one
hetero-ring atom, preferably selected from N, S and O, for example,
tetrahydrofuranyl, piperidinyl, and pyrrolidinyl.
[0081] Heterocycle-alkyl refers to a heterocycle-alkyl-group
wherein the heterocyclic and alkyl portions are in accordance with
the previous discussions. Suitable examples are pyridylmethyl,
thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, and
isoquinolinylmethyl.
[0082] Partially unsaturated carbocyclic structures are
non-aromatic monocyclic or bicyclic structures containing 5 to 14
carbon atoms, preferably 6 to 10 carbon atoms, wherein the ring
structure(s) contains at least one C=C bond. Suitable examples are
cyclopentenyl, cyclohexenyl, cyclohexadienyl, tetrahydronaphthenyl
and indan-2-yl.
[0083] Alkenyl refers to straight-chain or branched-chain aliphatic
radicals containing 2 to 12 carbon atoms in which one or more
--CH.sub.2--CH.sub.2-- structures are each replaced by
--CH.dbd.CH--. Suitable alkenyl groups are ethenyl, 1-propenyl,
2-methylethenyl, 1-butene, 2-butene, 1-pentenyl, and
2-pentenyl.
[0084] Alkynyl refers to straight-chain or branched-chain aliphatic
radicals containing 2 to 12 carbon atoms in which one or more
--CH.sub.2--CH.sub.2-- structures are each replaced by
--C.ident.C--. Suitable alkynyl groups are ethynyl, propynyl,
1-butynyl, and 2-butynyl.
[0085] Acyl refers to alkanoyl radicals having 1 to 13 carbon atoms
in which the alkyl portion can be substituted by halogen, alkyl,
aryl and/or alkoxy, or aroyl radicals having 7 to 15 carbon atoms
in which the aryl portion can be substituted by, for example,
halogen, alkyl and/or alkoxy. Suitable acyl groups include formyl,
acetyl, propionyl, butanoyl and benzoyl.
[0086] Substituted radicals preferably have 1 to 3 substituents,
especially 1 to 2 substituents.
[0087] In the compounds of Formula I, R.sup.1 is an alkyl group
having preferably 1 to 4 carbon atoms which is optionally
substituted by halogen, preferably fluorine or chlorine. In
particular, R.sup.1 is preferably methyl or difluoromethyl.
[0088] R.sup.2 is preferably cycloalkyl, particularly
cyclopentyl.
[0089] R.sup.2 is also preferably aryl or arylalkyl, particularly
substituted or unsubstituted phenyl or phenylalkyl, such as phenyl,
methylphenyl, methoxyphenyl, chlorophenyl, phenethyl, phenpropyl,
phenbutyl, phenylethenyl, phenoxyethyl, phenoxypropyl,
phenoxybutyl, chlorophenylethyl, methoxyphenylethyl,
chlorophenylethenyl, chlorophenoxyethyl, chlorophenypropyl,
methoxyphenpropyl, methoxyphenbutyl, chlorophenbutyl,
nitrophenbutyl, chlorophenylaminoethyl, and the like.
[0090] R.sup.2 is also preferably a partially unsaturated
carbocyclic groups, which is unsubstituted or substituted,
particularly cyclohexenyl, cyclohexadienyl, indan-2-yl.
[0091] R.sup.2 is also preferably an alkyl group having 1 to 8
carbon atoms, especially 1 to 4 carbon atoms, which is substituted
or unsubstituted, e.g., methyl, difluoromethyl, trifluoromethyl,
and methoxyethyl.
[0092] R.sup.2 is also preferably a heterocyclic or
heterocycle-alkyl group, particularly radicals in which the
heterocyclic group has 5 to 6 ring atoms and 1 to 2 hetero-ring
atoms selected from N, O and S, e.g., tetrahydrofuranyl,
pyrrolidinyl, pyrrolyl, pyridylmethyl, pyridylethyl, pyridylpropyl,
piperazinylmethyl, piperazinylethyl, methylpiperazinylethyl and the
like.
[0093] Preferred R.sup.2 include cyclopentyl, tetrahydrofuranyl,
CHF.sub.2, methoxyethyl, cyclopropylmethyl, phenethyl, phenpropyl,
phenylethenyl, phenoxyethyl, phenoxybutyl, phenylaminoethyl,
indan-2-yl, pyridylethyl, and pyridylpropyl.
[0094] In the compounds of Formulas I-III, R.sup.3 is preferably
aryl or heteroaryl, especially phenyl, naphthyl, biphenyl, furanyl,
pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, and isoquinolinyl,
which in each case is unsubstituted or is substituted one or more
times. Preferred substituents are OH, F, Cl, CF.sub.3, alkyl (such
as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN,
vinyl, CH.sub.2OH, CONHOH, CONH.sub.2, methylenedioxy, COOH, and
combinations thereof. R.sup.3 is preferably pyridyl or phenyl which
in each case is substituted or unsubstituted. For example, R.sup.3
can be phenyl substituted by halogen, COOH and/or CN.
[0095] In addition, when R.sup.3 is aryl, especially, phenyl,
preferred substituents include R.sup.4-L-, e.g., R.sup.4--,
R.sup.4--O--, R.sup.4--CO--, R.sup.4--NH--CO--,
R.sup.4--SO.sub.2--NH--, R.sup.4--SO.sub.2--NHCO--,
R.sup.4--SO.sub.2--NH-alkylene-O--, NH.sub.2-alkyl-NH--CO--,
R.sup.4-alkylene-NH--CO--, and alkyl-CO--NH-alkyl-. Other preferred
substituents include methyl, ethyl, Cl, F, CN, OCH.sub.3, CF.sub.3,
amino, nitro, CH.sub.2OH and COOH.
[0096] When R.sup.3 is aryl substituted by R.sup.4--SO.sub.2--NH--,
it is preferably a substituted phenyl group and R.sup.4 is
preferably methyl, ethyl, propyl or phenyl.
[0097] When R.sup.3 is aryl substituted by
R.sup.4--SO.sub.2--NH-alkylene-O--, it is preferably a substituted
phenyl. In such cases, R.sup.4 is preferably methyl, ethyl, propyl
or phenyl and alkylene is preferably --CH.sub.2--,
--CH.sub.2CH.sub.2-- or --CH.sub.2CH.sub.2CH.sub.2--.
[0098] When R.sup.3 is aryl substituted by R.sup.4-L-, it is
preferably substituted phenyl. In such cases, preferred R.sup.4
groups include phenyl, tetrazolyl, oxazinyl, piperazinyl,
methylpiperazinyl, pyridyl, methylpyridyl, pyrrolinyl,
methylpyrrolinyl, piperadinyl, or methylpiperadinyl, and L is
preferably a single bond, --O--, --CO--, --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2--O--, --CH.sub.2CH.sub.2--O--,
--CH.sub.2CH.sub.2CH.sub.2--O--,
--CH.sub.2--NH--CH.sub.2CH.sub.2--O--, --CO--NH--, --NH--CO--, or
--CONHSO.sub.2--.
[0099] R.sup.6 is preferably H or F, especially H.
[0100] In the compounds of Formula II, R.sup.7 can be an alkyl
group having preferably 2 to 4 carbon atoms which is optionally
substituted by halogen, preferably fluorine or chlorine.
[0101] R.sup.7 can also preferably be cycloalkyl, particularly
cyclopentyl or cyclohexyl.
[0102] R.sup.8 is preferably H or alkyl having 1 to 4 carbon atoms,
especially --C.sub.2H.sub.5.
[0103] In the compounds of Formula III, R.sup.9 is preferably
alkoxy having 1 to 4 carbon atoms, which is branched or unbranched
and which is unsubstituted or substituted one or more times by
halogen, e.g., --OCH.sub.3 or --OC.sub.2H.sub.5.
[0104] R.sup.10 is preferably --CO--C.sub.1-4-alkyl, e.g.,
--COCH.sub.3.
[0105] R.sup.11 is preferably --CH.sub.3.
[0106] R.sup.12 and R.sup.13 are each independently preferably
--CH.sub.3 or --CH.sub.2CH.sub.3.
[0107] X and Y are each preferably O or S, especially O.
[0108] G is preferably --CH.sub.2CH.sub.2--.
[0109] In addition, preferred PDE4 inhibitors in accordance with
the invention are compounds described by subformulas Ia-Ix,
IIa-IIf, and IIIa-IIIe which correspond, respectfively, to Formulas
I-III but exhibit the following preferred groups: [0110] Ia R.sup.1
is methyl or CHF.sub.2; [0111] R.sup.2 is alkyl, alkenyl, alkynyl,
cycloalkyl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, aryl, or
heterocyclic, in each case substituted or unsubstituted; and [0112]
R.sup.3 is aryl or heteroaryl, in each case substituted or
unsubstituted. [0113] Ib R.sup.1 is methyl or CHF.sub.2; and [0114]
R.sup.2 is cyclopentyl, CHF.sub.2, cyclopropylmethyl, pyridylethyl
(particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly
(3R)-tetrahydrofuranyl). [0115] Ic R.sup.1 is methyl or CHF.sub.2;
and [0116] R.sup.2 is cyclopentyl, CHF.sub.2, cyclopropylmethyl,
pyridylethyl (particularly 2-pyridylethyl), or tetrahydrofuranyl
(particularly (3R)-tetrahydrofuranyl); and [0117] R.sup.3 is aryl
or heteroaryl, in each case substituted or unsubstituted. [0118] Id
R.sup.1 is methyl or CHF.sub.2; [0119] R.sup.2 is cyclopentyl; and
[0120] R.sup.3 is substituted or unsubstituted aryl or heteroaryl.
[0121] Ie R.sup.1 is methyl; [0122] R.sup.2 is cyclopentyl; and
[0123] R.sup.3 is phenyl which is substituted or unsubstituted.
[0124] If R.sup.1 is methyl; [0125] R.sup.2 is cyclopentyl; and
[0126] R.sup.3 is phenyl or phenyl substituted with 1 to 3
substituents. [0127] Ig R.sup.1 is methyl; [0128] R.sup.2 is
cyclopentyl; and [0129] R.sup.3 is phenyl, naphthyl, biphenyl,
pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, quinolinyl, or
isoquinolinyl, in each case substituted or unsubstituted. [0130] Ih
R.sup.1 is methyl or CHF.sub.2. [0131] Ii R.sup.1 is methyl or
CHF.sub.2, and [0132] B is N-[0. [0133] Ij R.sup.1 is methyl or
CHF.sub.2, and [0134] R.sup.2 is cyclopentyl, CHF.sub.2,
cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or
tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl). [0135] Ik
R.sup.1 is methyl or CHF.sub.2, [0136] B is N--O, and [0137]
R.sup.2 is cyclopentyl, CHF.sub.2, cyclopropylmethyl, pyridylethyl
(particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly
(3R)-tetrahydrofuranyl). [0138] Il R.sup.1 is methyl or CHF.sub.2,
and [0139] R.sup.3 is 3-pyridyl or phenyl, which in each case is
substituted or unsubstituted. [0140] Im R.sup.1 is methyl or
CHF.sub.2, [0141] B is N--O, and [0142] R.sup.3 is 3-pyridyl or
phenyl, which in each case is substituted or unsubstituted. [0143]
In R.sup.1 is methyl or CHF.sub.2, [0144] R.sup.2 is cyclopentyl,
CHF.sub.2, cyclopropylmethyl, pyridylethyl (particularly
2-pyridylethyl), or tetrahydrofuranyl (particularly
(3R)-tetrahydrofuranyl), and [0145] R.sup.3 is 3-pyridyl or phenyl,
which in each case is substituted or unsubstituted. [0146] Io
R.sup.1 is methyl or CHF.sub.2, [0147] B is N--O, [0148] R.sup.2 is
cyclopentyl, CHF.sub.2, cyclopropylmethyl, pyridylethyl
(particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly
(3R)-tetrahydrofuranyl), and [0149] R.sup.3 is 3-pyridyl or phenyl,
which in each case is substituted or unsubstituted. [0150] Ip
R.sup.1 is methyl or CHF.sub.2, and [0151] R.sup.3 is phenyl which
is substituted in the 3-- or 4-position. [0152] Iq R.sup.1 is
methyl or CHF.sub.2, [0153] B is N--O, and [0154] R.sup.3 is phenyl
which is substituted in the 3-- or 4-position. [0155] Ir R.sup.1 is
methyl or CHF.sub.2, [0156] R.sup.2 is cyclopentyl, CHF.sub.2,
cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or
tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and [0157]
R.sup.3 is phenyl which is substituted in the 3-- or 4-position.
[0158] Is R.sup.1 is methyl or CHF.sub.2, [0159] B is N--O, [0160]
R.sup.2 is cyclopentyl, CHF.sub.2, cyclopropylmethyl, pyridylethyl
(particularly 2-pyridylethyl), or tetrahydrofuranyl (particularly
(3R)-tetrahydrofuranyl), and [0161] R.sup.3 is phenyl which is
substituted in the 3-- or 4-position. [0162] It R.sup.1 is methyl
or CHF.sub.2, and [0163] R.sup.3 is 3-pyridyl, 3-COOH-phenyl,
3-Cl-phenyl, 3-cyano-phenyl, 3-ethylsulfonamido-phenyl,
3-tetrazol-5-yl-phenyl, 3-hydroxymethyl-phenyl, 4-pyridyl,
4-COOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamido-phenyl,
4-tetrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl. [0164] Iu
R.sup.1 is methyl or CHF.sub.2, [0165] B is N--O, and [0166]
R.sup.3 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl,
3-ethylsulfonamido-phenyl, 3-tetrazol-5-yl-phenyl,
3-hydroxymethyl-phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl,
4-ethylsulfonamido-phenyl, 4-tetrazol-5-yl-phenyl, or
4-hydroxymethyl-phenyl. [0167] Iv R.sup.1 is methyl or CHF.sub.2,
[0168] R.sup.2 is cyclopentyl, CHF.sub.2, cyclopropylmethyl,
pyridylethyl (particularly 2-pyridylethyl), or tetrahydrofuranyl
(particularly (3R)-tetrahydrofuranyl), and [0169] R.sup.3 is
3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl,
3-ethylsulfonamido-phenyl, 3-tetrazol-5-yl-phenyl,
3-hydroxymethyl-phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl,
4-ethylsulfonamido-phenyl, 4-tetrazol-5-yl-phenyl, or
4-hydroxymethyl-phenyl. [0170] Iw R.sup.1 is methyl or CHF.sub.2,
[0171] B is N--O, [0172] R.sup.2 is cyclopentyl, CHF.sub.2,
cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or
tetrahydrofuranyl (particularly (3R)-tetrahydrofuranyl), and [0173]
R.sup.3 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl,
3-ethylsulfonamido-phenyl, 3-tetrazol-5-yl-phenyl,
3-hydroxymethyl-phenyl, 3-nitro-phenyl, 4-pyridyl, 4-COOH-phenyl,
4-cyano-phenyl, 4-ethylsulfonamido-phenyl, 4-tetrazol-5-yl-phenyl,
or 4-hydroxymethyl-phenyl. [0174] Ix Any of subformulas Ia-Iw
wherein R.sup.6 is H. [0175] IIa R.sup.3 is H or is aryl or
heteroaryl, in each case substituted or unsubstituted. [0176] IIb
R.sup.7 is cycloalkyl; and [0177] R.sup.8 is H or C.sub.2H.sub.5.
[0178] IIc R.sup.7 is cycloalkyl; [0179] R.sup.8 is H or
C.sub.2H.sub.5; and [0180] R.sup.3 is H or is aryl or heteroaryl,
in each case substituted or unsubstituted. [0181] IId R.sup.7 is
cyclopentyl; [0182] R.sup.8 is H or C.sub.2H.sub.5; and [0183]
R.sup.3 is H or is aryl or heteroaryl, in each case substituted or
unsubstituted. [0184] IIe R.sup.7 is cyclopentyl; [0185] R.sup.8 is
H or C.sub.2H.sub.5; and [0186] R.sup.3 is phenyl which is
substituted or unsubstituted. [0187] IIf Any of subformulas IIa-IIe
wherein R.sup.6 is H. [0188] IIIa R.sup.3 is H or is aryl or
heteroaryl, in each case substituted or unsubstituted. [0189] IIIb
R.sup.9 is alkoxy having 1 to 4 carbon atoms; [0190] R.sup.10 is
COCH.sub.3 or
[0190] ##STR00005## [0191] R.sup.11 is --CH.sub.3; [0192] X and Y
are both O or S; and [0193] G is --CH.sub.2CH.sub.2--. [0194] IIIc
R.sup.3 is H or is aryl or heteroaryl, in each case substituted or
unsubstituted; [0195] R.sup.9 is alkoxy having 1 to 4 carbon atoms;
[0196] R.sup.10 is COCH.sub.3 or
[0196] ##STR00006## [0197] R.sup.11 is --CH.sub.3; [0198] X and Y
are both O or S; and [0199] G is --CH.sub.2CH.sub.2--.
[0200] IIId R.sup.3 is phenyl which is substituted or
unsubstituted; [0201] R.sup.9 is alkoxy having 1 to 4 carbon atoms;
[0202] R.sup.10 is COCH.sub.3 or
[0202] ##STR00007## [0203] R.sup.11 is --CH.sub.3; [0204] X and Y
are both O or S; and [0205] G is --CH.sub.2CH.sub.2--. [0206] IIIe
Any of subformulas IIIa-IIId wherein R.sup.6 is H.
[0207] According to a further aspect of the invention, the
compounds of formulas I-III are selected from the following: [0208]
a)
3'-Chloro-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)diphenylami-
ne (Which can also be called
3-Chloro-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)an-
iline) [0209] b)
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)dip-
henylamine (Which can also be called
3-Chloro-N-(4-methoxy-3-tetrahydrofuryloxyphenyl)-N-(1-oxy-3-pyridylmethy-
l)aniline) [0210] c)
3'-Cyano-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)d-
iphenylamine (Which can also be called
3-Cyano-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)aniline) [0211] d)
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-(3-tetrahydrofuryloxy)diphe-
nylamine (Which can also be called
N-(4-Difluoromethoxy-3-tetrahydrofuryloxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)aniline) [0212] e)
3,4-Bis(difluoromethoxy)-N-(1-oxy-3-pyridylmethyl)diphenylamine
(Which can also be called
N-[3,4-Bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)aniline)
[0213] f)
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine (Which can also be called
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)aniline [0214] g)
3'-Cyano-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofu-
ryloxy)diphenylamine (Which can also be called
3-Cyano-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)aniline) [0215] h)
3'-Chloro-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrof-
uryloxy)diphenylamine (Which can also be called
3-Chloro-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-
-oxy-3-pyridylmethyl)aniline) [0216] i)
4'-tert-Butyldimethylsilyloxy-3-cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine (Which can also be called
4-tert-Butyldimethylsilyloxy-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-ox-
y-3-pyridylmethyl)aniline) [0217] j)
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid (Which can also be called
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid) [0218] k)
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-aminoben-
zoic acid (Which can also be called
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid) [0219] l)
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid (Which can also be called
3-Amino-N-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)benzoic acid) [0220] m)
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid (Which can also be called
3-Amino-N-[4-methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylme-
thyl)benzoic acid) [0221] n)
N-[3,4-Bis(difluoromethoxy)phenyl)-N-(1-oxy-3-pyridylmethyl)-3-aminobenzo-
ic acid (Which can also be called
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid) [0222] o)
N-[4-methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid (Which can also be called
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)benzoic acid) [0223] p)
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-amin-
obenzoic acid (Which can also be called
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid) [0224] q)
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)-3-aminobenzoic acid (Which can also be called
3-Amino-N-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyrid-
ylmethyl)benzoic acid) [0225] r)
N-[3-(4-Chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyridylmeth-
yl)-3-aminobenzoic acid (Which can also be called
3-Amino-N-[3-(4-chlorophenyl)prop-1-yloxy-4-methoxyphenyl]-N-(1-oxy-3-pyr-
idylmethyl)benzoic acid) [0226] s)
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-amin-
obenzoic acid (Which can also be called
3-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl-
)benzoic acid) [0227] t)
N-[3-(2-Indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-aminoben-
zoic acid (Which can also be called
3-Amino-N-[3-(2-indanyloxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid) [0228] u)
N-[4-Methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3--
aminobenzoic acid (Which can also be called
3-Amino-N-[4-methoxy-3-(3-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylme-
thyl)benzoic acid) [0229] v)
N-[4-Methoxy-3-((3R)-tetrahydrofuryloxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-
-3-aminobenzoic acid (Which can also be called
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)benzoic acid) [0230] w)
N-[3-(2-Methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-3-amino-
benzoic acid (Which can also be called
3-Amino-N-[3-(2-methoxyethoxy)-4-methoxyphenyl]-N-(1-oxy-3-pyridylmethyl)-
benzoic acid) [0231] x)
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-
-tetrazol-5-yl)diphenylamine (which can also be called
N-(3-Cyclopropylmethyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl)-4-(2H-tetrazol-5-yl)aniline) [0232] y)
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl-
)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-(2H-tetr-
azol-5-yl)aniline) [0233] z)
3-Cyclopentyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-tetrazol-5-yl-
)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetr-
azol-5-yl)aniline) [0234] aa)
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4'-(2H-te-
trazol-5-yl)diphenylamine (Which can also be called
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-(2H-tetrazol-5-yl)aniline) [0235] bb)
3-Cyclopropylmethyloxy-4-methoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazo-
l-5-yl)diphenylamine (Which can also be called
N-(3-Cyclopropylmethyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-(2-
H-tetrazol-5-yl)aniline) [0236] cc)
4-Difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3-((3R)-tetrahydrofuryloxy)-4-
'-(2H-tetrazol-5-yl)diphenylamine (Which can also be called
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-4-(2H-tetrazol-5-yl)aniline) [0237] dd)
3-Cyclopentyloxy-4-difluromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetraz-
ol-5-yl)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-difluromethoxyphenly)-N-(1-oxy-3-pyridylmethyl)-4-(-
2H-tetrazol-5-yl)aniline) [0238] ee)
3-Cyclopropylmethyloxy-4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-3'-(2H-
-tetrazol-5-yl)diphenylamine (Which can also be called
N-(3-Cyclopropylmethyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylmeth-
yl)-3-(2H-tetrazol-5-yl)aniline) [0239] ff)
Bis-3,4-difluoromethoxy-N-(1-oxy-3-pyridylmethyl)-4'-(2H-tetrazol-5-yl)di-
phenylamine (Which can also be called
N-[3,4-Bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-(2H-tetraz-
ol-5-yl)aniline) [0240] gg)
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyridylmeth-
yl)amine (Which can also be called
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)pyr-
idine) [0241] hh)
N-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-pyr-
idylmethyl)amine (Which can also be called
3-Amino-N-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)pyridine) [0242] ii)
N-(3-Cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(3-pyridyl)-N-(1-oxy-3-
-pyridylmethyl)amine (Which can also be called
3-Amino-N-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-N-(1-oxy-3-pyrid-
ylmethyl)pyridine) [0243] jj)
N-(4-Difluoromethoxy-3-(3R)-tetrahydrofuryloxyphenyl)-N-(3-pyridyl)-N-(1--
oxy-3-pyridylmethyl)amine (Which can also be called
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)pyridine) [0244] kk)
3-Cyclopentyloxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-3-ethylsulfonylamino-N-(1-oxy-3-pyri-
dylmethyl)aniline) [0245] ll)
3-Cyclopentyloxy-4-methoxy-3'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-3-(1-propy-
lsulfonylamino)aniline) [0246] mm)
3-Cyclopentyloxy-4'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyridylmethy-
l)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-4-ethylsulfonylamino-N-(1-oxy-3-pyri-
dylmethyl)aniline) [0247] nn)
3-Cyclopentyloxy-4-methoxy-4'-(1-propanesulfonylamino)-N-(1-oxy-3-pyridyl-
methyl)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)-4-(1-propa-
nesulfonylamino)aniline) [0248]
oo)3-Cyclopropylmethoxy-3'-ethanesulfonylamino-4-methoxy-N-(1-oxy-3-pyrid-
ylmethyl)diphenylamine (Which can also be called
N-(3-Cyclopropylmethoxy-4-methoxyphenyl)-3-ethylsulfonylamino-N-(1-oxy-3--
pyridylmethyl)aniline) [0249] pp)
4-Difluoromethoxy-3'-ethanesulfonylamino-N-(1-oxy-3-pyridylmethyl)-3-[(3R-
)-tetrahydrofuryloxy]diphenylamine (Which can also be called
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-3-ethylsulfon-
ylamino-N-(1-oxy-3-pyridylmethyl)aniline) [0250] qq)
4-Methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diphenylamine
(Which can also be called
N-[4-Methoxy-3-(2-(2-pyridyl)ethoxyphenyl)]-N-(1-oxy-3-pyridylmethyl)anil-
ine) [0251] rr)
4-Methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]diphenylam-
ine (Which can also be called
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)aniline) [0252] ss)
3'-Chloro-4-methoxy-3-[2-(2-pyridyl)ethoxy]-N-(1-oxy-3-pyridylmethyl)diph-
enylamine (Which can also be called
3-Chloro-N-[4-methoxy-3-(2-(2-pyridyl)ethoxy)]-N-(1-oxy-3-pyridylmethyl)a-
niline) [0253] tt)
3'-Chloro-4-methoxy-N-(1-oxy-3-pyridylmethyl)-3-[(3R)-tetrahydrofuryloxy]-
diphenylamine (Which can also be called
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline) [0254] uu)
3-Cyclopentyloxy-4-methoxy-4'-[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-p-
yridylmethyl)diphenylamine (Which can also be called
N-(3-Cyclopentyloxy-4-methoxyphenyl)-4-
[2-(5-oxopyrrolidinyl)methoxy]-N-(1-oxy-3-pyridylmethyl)aniline)
[0255]
vv)3-Cyclopentyloxy-4-methoxy-N-(3-aminocarbonylphenyl)-N-(1-oxy-3-pyridy-
lmethyl)aniline (Which can also be called
3-Aminocarbonyl-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylme-
thyl)aniline) [0256] ww)
3,4-Bisdifluoromethoxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy-3-pyridylmet-
hyl)aniline (Which can also be called
3-Amino-N-[3,4-Bis(difluoromethoxy)phenyl]-4-chloro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid) [0257] xx)
3,4-Bisdifluoromethoxy-N-(4-(1-pyrrol-1-yl)phenyl)-N-(1-oxy-3-pyridylmeth-
yl)aniline (Which can also be called
N-[3,4-Bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-(1-pyrroly-
l)aniline [0258] yy)
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxy-4-chlorophenyl)-N-(1-oxy--
3-pyridylmethyl)aniline (Which can also be called
3-Amino-4-chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-
-oxy-3-pyridylmethyl)benzoic acid) [0259] zz)
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-carboxyphenyl)-N-(1-oxy-4-pyridyl-
methyl)aniline (Which can also be called
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-4-py-
ridylmethyl)benzoic acid [0260] aaa)
4-Methoxy-3-(R)-tetrahydrofuryloxy-N-(3-pyridyl)-N-(1-oxy-4-pyridylmethyl-
)aniline (Which can also be called
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-4-py-
ridylmethyl)pyridine) [0261] bbb)
3-Cyclopentyloxy-4-methoxy-N-(4-carboxy-3-chlorophenyl)-N-(1-oxy-3-pyridy-
lmethyl)aniline (Which can also be called
4-Amino-3-chloro-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylm-
ethyl)benzoic acid) [0262] ccc)
2-Acetyl-7-methoxy-4-(N-(4-cyanophenyl)-N-(1-oxy-3-pyridylmethyl))aminobe-
nzofuran (Which can also be called
2-Acetyl-4-amino-N-(4-cyanophenyl)-7-methoxy-N-(1-oxy-3-pyridylmethyl)ben-
zofuran) [0263] ddd)
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-4-pyridylmethyl))aminobenzofuran
(Which can also be called
2-Acetyl-4-amino-7-methoxy-N-(1-oxy-4-pyridylmethyl)-N-phenyl-benzofuran)
[0264] eee)
2-Acetyl-7-methoxy-4-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))amino-
benzofuran (Which can also be called
2-Acetyl-4-amino-N-(3-carboxyphenyl)-7-methoxy-N-(1-oxy-3-pyridylmethyl)b-
enzofuran [0265] fff)
1-Cyclopentyl-3-ethyl-6-(N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethyl))am-
inoindazole (Which can also be called
6-Amino-1-cyclopentyl-3-ethyl-N-(3-carboxyphenyl)-N-(1-oxy-3-pyridylmethy-
l)indazole) [0266] ggg)
2-Acetyl-7-methoxy-4-(N-(4-acetylphenyl)-N-(1-oxy-3-pyridylmethyl))aminob-
enzofuran (Which can also be called
2-Acetyl-N-(4-acetylphenyl)-4-amino-7-methoxy-N-(1-oxy-3-pyridylmethyl)be-
nzofuran) [0267] hhh)
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfonylamino-
carbonyl-N-(1-oxy-3-pyridylmethyl)aniline [0268] iii)
4-(4-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline [0269] jjj)
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline [0270] kkk)
3-Amino-N-(5-fluoro-1-oxy-3-pyridylmethyl)-N-(4-methoxy-3-((3R)-3-tetrahy-
drofuranyl)oxyphenyl]benzoic acid [0271] lll)
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-2-pyridylmethyl)ben-
zoic acid [0272] mmm)
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-5-trifluoromethylbenzoic acid [0273] nnn)
4-Ethylsulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxy-
phenyl]-N-(1-oxy-3-pyridylmethyl)aniline [0274] ooo)
4-(2-Fluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline [0275] ppp)
4-(3-Chlorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrahydro-
furanyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline [0276] qqq)
3-Amino-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-py-
ridylmethyl)-6-trifluoromethylbenzoic acid [0277] rrr)
4-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid [0278] sss)
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-methylsulfo-
nylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline [0279] ttt)
N-[4-Methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmet-
hyl)-4-phenylsulfonylaminocarbonylaniline [0280] uuu)
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid [0281] vvv)
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(5-fluoro-1-oxy-3-pyridylm-
ethyl)benzoic acid [0282] www)
3-Amino-N-[4-difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1--
oxy-3-pyridylmethyl)benzoic acid [0283] xxx)
3-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid [0284] yyy)
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-5-fluoro-N-(1-oxy-3-pyridylm-
ethyl)benzoic acid
[0285] zzz)
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-5-fluoro-N-(1-oxy-3-pyridylmet-
hyl)benzoic acid [0286] aaaa)
4-Amino-N-(3-cyclobutyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid [0287] bbbb)
4-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid [0288] cccc)
4-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid [0289] dddd)
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-(3,4-difluo-
rophenyl)sulfonylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline
[0290] eeee)
4-Amino-N-(3-cyclopropylmethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridyl-
methyl)benzoic acid [0291] ffff)
N-[3,4-Bis(difluoromethoxy)phenyl]-4-(4-fluorophenyl)sulfonylaminocarbony-
l-N-(1-oxy-3-pyridylmethyl)aniline [0292] gggg)
4-(2,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline [0293]
hhhh)
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-[4-methoxy-3-((3R)-3-tetrah-
ydrofuranyl)oxyphenyl]-N-(1-oxy-3-pyridylmethyl)aniline [0294]
iiii)
N-[4-Difluoromethoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-4-ethylsulfon-
ylaminocarbonyl-N-(1-oxy-3-pyridylmethyl)aniline [0295] jjjj)
3-Amino-N-(3,4-dimethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid [0296] kkkk)
3-Amino-N-(3-ethoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid [0297] llll)
3-Amino-N-(3-isopropoxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benzoic
acid [0298] mmmm)
4-(3,4-Difluorophenyl)sulfonylaminocarbonyl-N-(3-ethoxy-4-methoxyphenyl)--
N-(1-oxy-3-pyridylmethyl)aniline [0299] nnnn)
3-Amino-N-[3,4-bis(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benzo-
ic acid [0300] oooo)
3-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid [0301] pppp)
4-Amino-N-(4-difluoromethoxy-3-ethoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid [0302] qqqq)
3-Amino-N-(4-difluoromethoxy-3-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)be-
nzoic acid [0303] rrrr)
2-Acetyl-7-methoxy-4-(N-phenyl-N-(1-oxy-3-pyridyl-methyl))aminobenzofuran-
, [0304] ssss)
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine, [0305] tttt)
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[2-(2-tet-
rahydropyranyl)-2H-tetrazol-5-yl]aniline, [0306] uuuu)
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetra-
zol-5-yl)aniline; and [0307] pharmaceutically acceptable salts
thereof, wherein optically active compounds can be in the form of
their separate enantiomers or mixtures thereof, including racemic
mixtures.
[0308] Preferred aspects include pharmaceutical compositions
comprising a compound of this invention and a pharmaceutically
acceptable carrier and, optionally, another active agent as
discussed below; a method of inhibiting a PDE4 enzyme, especially
an isoenzyme, e.g., as determined by a conventional assay or one
described herein, either in vitro or in vivo (in an animal, e.g.,
in an animal model, or in a mammal or in a human); a method of
treating neurological syndrome, e.g., loss of memory, especially
long-term memory, cognitive impairment or decline, memory
impairment, etc. a method of treating a disease state modulated by
PDE4 activity, in a mammal, e.g., a human, e.g., those mentioned
herein.
[0309] The compounds of the present invention may be prepared
conventionally.
[0310] Some of the processes which can be used are described below.
All starting materials are known or can be conventionally prepared
from known starting materials.
##STR00008##
[0311] The reaction scheme shown above is for illustrative purposes
only and should not be viewed as limiting the scope of the
synthetic methods available for the production of the compounds
described within this application. Pyridine N-oxides can be
produced by methods common witihn the art, such as by the reaction
of the corresponding pyridine with peroxides, e.g., hydrogen
peroxide, mCPBA or peracetic acid, in halogenated solvents, such as
chloroform or dichloromethane, or in polar protic solvents, such as
acetic acid. Thus, for example, the reaction of
3-chloromethylpyridine with peracetic acid in acetic
acid/chloroform yields the desired 3-chloromethylpyridine N-oxide
as a white crystalline solid.
[0312] Subsequently, the anion of the diphenylamine or substituted
aniline is prepared by reaction with a strong base, such as sodium
hydride, LDA, or potassium hexamethyldisilylazide, in polar aprotic
solvents such as DMF or THF. Treatment of the anion of the
diphenylamine or substituted aniline with a halomethylpyridine
N-oxide provides the desired compounds.
[0313] Many of these synthetic procedures are described more fully
in the examples below.
[0314] One of ordinary skill in the art will recognize that some of
the compounds of Formulae I-III can exist in different geometrical
isomeric forms. In addition, some of the compounds of the present
invention possess one or more asymmetric carbon atoms and are thus
capable of existing in the form of optical isomers, as well as in
the form of racemic or nonracemic mixtures thereof, and in the form
of diastereomers and diastereomeric mixtures inter alia. All of
these compounds, including cis isomers, trans isomers, diastereomic
mixtures, racemates, nonracemic mixtures of enantiomers, and
substantially pure and pure enantiomers, are within the scope of
the present invention. Substantially pure enantiomers contain no
more than 5% w/w of the corresponding opposite enantiomer,
preferably no more than 2%, most preferably no more than 1%.
[0315] The optical isomers can be obtained by resolution of the
racemic mixtures according to conventional processes, for example,
by the formation of diastereoisomeric salts using an optically
active acid or base or formation of covalent diastereomers.
Examples of appropriate acids are tartaric, diacetyltartaric,
dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid.
Mixtures of diastereoisomers can be separated into their individual
diastereomers on the basis of their physical and/or chemical
differences by methods known to those skilled in the art, for
example, by chromatography or fractional crystallization. The
optically active bases or acids are then liberated from the
separated diastereomeric salts. A different process for separation
of optical isomers involves the use of chiral chromatography (e.g.,
chiral HPLC columns), with or without conventional derivation,
optimally chosen to maximize the separation of the enantiomers.
Suitable chiral HPLC columns are manufactured by Diacel, e.g.,
Chiracel OD and Chiracel OJ among many others, all routinely
selectable. Enzymatic separations, with or without derivitization,
are also useful. The optically active compounds of Formulae I-III
can likewise be obtained by chiral syntheses utilizing optically
active starting materials.
[0316] In addition, one of ordinary skill in the art will recognize
that the compounds can be used in different enriched isotopic
forms, e.g., enriched in the content of .sup.2II, .sup.3H,
.sup.11C, .sup.13C and/or .sup.14C. In one particular embodiment,
the compounds are deuterated.
[0317] Such deuterated forms can be made the procedure described in
U.S. Pat. Nos. 5,846,514 and 6,334,997. As described in U.S. Pat.
Nos. 5,846,514 and 6,334,997, deuteration can improve the efficacy
and increase the duration of action of drugs.
[0318] Deuterium substituted compounds can be synthesized using
various methods such as described in: Dean, Dennis C.; Editor.
Recent Advances in the Synthesis and Applications of Radiolabeled
Compounds for Drug Discovery and Development. [In: Cum, Pharm.
Des., 2000; 6(10)] (2000), 110 pp. CAN 133:68895 AN 2000:473538
CAPLUS; Kabalka, George W.; Varma, Rajender S. The synthesis of
radiolabeled compounds VIA organometallic intermediates.
Tetrahedron (1989), 45(21), 6601-21, CODEN: TETRAB ISSN:0040-4020.
CAN 112:20527 AN 1990:20527 CAPLUS; and Evans, E. Anthony.
Synthesis of radiolabeled compounds, J. Radioanal. Chem. (1981),
64(1-2), 9-32. CODEN: JRACBN ISSN:0022-4081, CAN 95:76229 AN
1981:476229 CAPLUS.
[0319] The present invention also relates to useful forms of the
compounds as disclosed herein, such as pharmaceutically acceptable
salts and prodrugs of all the compounds of the present invention.
Pharmaceutically acceptable salts include those obtained by
reacting the main compound, functioning as a base, with an
inorganic or organic acid to form a salt, for example, salts of
hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic
acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic
acid and citric acid. Pharmaceutically acceptable salts also
include those in which the main compound functions as an acid and
is reacted with an appropriate base to form, e.g., sodium,
potassium, calcium, mangnesium, ammonium, and choline salts. Those
skilled in the art will further recognize that acid addition salts
of the claimed compounds may be prepared by reaction of the
compounds with the appropriate inorganic or organic acid via any of
a number of known methods. Alternatively, alkali and alkaline earth
metal salts are prepared by reacting the compounds of the invention
with the appropriate base via a variety of known methods.
[0320] The following are further examples of acid salts that can be
obtained by reaction with inorganic or organic acids: acetates,
adipates, alginates, citrates, aspartates, benzoates,
benzenesulfonates, bisulfates, butyrates, camphorates,
digluconates, cyclopentanepropionates, dodecylsulfates,
ethanesulfonates, glucoheptanoates, glycerophosphates,
hemisulfates, heptanoates, hexanoates, fumarates, hydrobromides,
hydroiodides, 2-hydroxy-ethanesulfonates, lactates, maleates,
methanesulfonates, nicotinates, 2-naphthalenesulfonates, oxalates,
palmoates, pectinates, persulfates, 3-phenylpropionates, picrates,
pivalates, propionates, succinates, tartrates, thiocyanates,
tosylates, mesylates and undecanoates.
[0321] Preferably, the salts formed are pharmaceutically acceptable
for administration to mammals. However, pharmaceutically
unacceptable salts of the compounds are suitable as intermediates,
for example, for isolating the compound as a salt and then
converting the salt back to the free base compound by treatment
with an alkaline reagent. The free base can then, if desired, be
converted to a pharmaceutically acceptable acid addition salt.
[0322] The compounds of the invention can be administered alone or
as an active ingredient of a formulation. Thus, the present
invention also includes pharmaceutical compositions of compounds of
Formulas I-III containing, for example, one or more
pharmaceutically acceptable carriers.
[0323] Numerous standard references are available that describe
procedures for preparing various formulations suitable for
administering the compounds according to the invention. Examples of
potential formulations and preparations are contained, for example,
in the Handbook of Pharmaceutical Excipients, American
Pharmaceutical Association (current edition); Pharmaceutical Dosage
Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current
edition, published by Marcel Dekker, Inc., as well as Remington's
Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current
edition).
[0324] In view of their high degree of PDE4 inhibition, the
compounds of the present invention can be administered to anyone
requiring or desiring PDE4 inhibition, and/or enhancement of
cognition. Administration may be accomplished according to patient
needs, for example, orally, nasally, parenterally (subcutaneously,
intraveneously, intramuscularly, intrasternally and by infusion),
by inhalation, rectally, vaginally, topically, locally,
transdermally, and by ocular administration.
[0325] Various solid oral dosage forms can be used for
administering compounds of the invention including such solid forms
as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk
powders. The compounds of the present invention can be administered
alone or combined with various pharmaceutically acceptable
carriers, diluents (such as sucrose, mannitol, lactose, starches)
and excipients known in the art, including but not limited to
suspending agents, solubilizers, buffering agents, binders,
disintegrants, preservatives, colorants, flavorants, lubricants and
the like. Time release capsules, tablets and gels are also
advantageous in administering the compounds of the present
invention.
[0326] Various liquid oral dosage forms can also be used for
administering compounds of the invention, including aqueous and
non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
Such dosage forms can also contain suitable inert diluents known in
the art such as water and suitable excipients known in the art such
as preservatives, wetting agents, sweeteners, flavorants, as well
as agents for emulsifying and/or suspending the compounds of the
invention. The compounds of the present invention may be injected,
for example, intravenously, in the form of an isotonic sterile
solution. Other preparations are also possible.
[0327] Suppositories for rectal administration of the compounds of
the present invention can be prepared by mixing the compound with a
suitable excipient such as cocoa butter, salicylates and
polyethylene glycols. Formulations for vaginal administration can
be in the form of a pessary, tampon, cream, gel, paste, foam, or
spray formula containing, in addition to the active ingredient,
such suitable carriers as are known in the art.
[0328] For topical administration the pharmaceutical composition
can be in the form of creams, ointments, liniments, lotions,
emulsions, suspensions, gels, solutions, pastes, powders, sprays,
and drops suitable for administration to the skin, eye, ear or
nose. Topical administration may also involve transdermal
administration via means such as transdermal patches.
[0329] Aerosol formulations suitable for administering via
inhalation also can be made. For example, for treatment of
disorders of the respiratory tract, the compounds according to the
invention can be administered by inhalation in the form of a powder
(e.g., micronized) or in the form of atomized solutions or
suspensions. The aerosol formulation can be placed into a
pressurized acceptable propellant.
[0330] The compounds can be administered as the sole active agent
or in combination with other pharmaceutical agents such as other
agents used in the treatment of cognitive impairment and/or in the
treatment of psychosis, e.g., other PDE4 inhibitors, calcium
channel blockers, chloinergic drugs, adenosine receptor modulators,
amphakines NMDA-R modulators, mGluR modulators, and cholinesterase
inhibitors (e.g., donepezil, rivastigimine, and glanthanamine). In
such combinations, each active ingredient can be administered
either in accordance with their usual dosage range or a dose below
its usual dosage range.
[0331] The present invention further includes methods of treatment
that involve inhibition of PDE4 enzymes. Thus, the present
invention includes methods of selective inhibition of PDE4 enzymes
in animals, e.g., mammals, especially humans, wherein such
inhibition has a therapeutic effect, such as where such inhibition
may relieve conditions involving neurological syndromes, such as
the loss of memory, especially long-term memory. Such methods
comprise administering to an animal in need thereof, especially a
mammal, most especially a human, an inhibitory amount of a
compound, alone or as part of a formulation, as disclosed
herein.
[0332] The condition of memory impairment is manifested by
impairment of the ability to learn new information and/or the
inability to recall previously learned information. Memory
impairment is a primary symptom of dementia and can also be a
symptom associated with such diseases as Alzheimer's disease,
schizophrenia, Parkinson's disease, Huntington's disease, Pick's
disease, Creutzfeld-Jakob disease, HIV, cardiovascular disease, and
head trauma as well as age-related cognitive decline.
[0333] Dementias are diseases that include memory loss and
additional intellectual impairment separate from memory. The
present invention includes methods for treating patients suffering
from memory impairment in all forms of dementia. Dementias are
classified according to their cause and include: neurodegenerative
dementias (e.g., Alzheimer's, Parkinson's disease, Huntington's
disease, Pick's disease), vascular (e.g., infarcts, hemorrhage,
cardiac disorders), mixed vascular and Alzheimer's, bacterial
meningitis, Creutzfeld-Jacob Disease, multiple sclerosis, traumatic
(e.g., subdural hematoma or traumatic brain injury), infectious
(e.g., HIV), genetic (down syndrome), toxic (e.g., heavy metals,
alcohol, some medications), metabolic (e.g., vitamin B12 or folate
deficiency), CNS hypoxia, Cushing's disease, psychiatric (e.g.,
depression and schizophrenia), and hydrocephalus.
[0334] The present invention includes methods for dealing with
memory loss separate from dementia, including mild cognitive
impairment (MCI) and age-related cognitive decline. The present
invention includes methods of treatment for memory impairment as a
result of disease. In another application, the invention includes
methods for dealing with memory loss resulting from the use of
general anesthetics, chemotherapy, radiation treatment,
post-surgical trauma, and therapeutic intervention.
[0335] The compounds may be used to treat psychiatric conditions
including schizophrenia, bipolar or manic depression, major
depression, and drug addiction and morphine dependence. These
compounds may enhance wakefulness. PDE4 inhibitors can be used to
raise cAMP levels and prevent neurons from undergoing apoptosis.
PDE4 inhibitors are also known to be anti-inflammatory. The
combination of anti-apoptotic and anti-inflammatory properties make
these compounds useful to treat neurodegeneration resulting from
any disease or injury, including stroke, spinal cord injury,
Alzheimer's disease, multiple sclerosis, amylolaterosclerosis
(ALS), and multiple systems atrophy (MSA).
[0336] Thus, in accordance with a preferred embodiment, the present
invention includes methods of treating patients suffering from
memory impairment due to, for example, Alzheimer's disease,
multiple sclerosis, amylolaterosclerosis (ALS), multiple systems
atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's
disease, Pick's disease, Creutzfeld-Jakob disease, Rubenstein-Taybi
syndrome (RSTS), depression, aging, head trauma, stroke, spinal
cord injury, CNS hypoxia, cerebral senility, diabetes associated
cognitive impairment, memory deficits from early exposure of
anesthetic agents, multiinfarct dementia and other neurological
conditions including acute neuronal diseases, as well as HIV and
cardiovascular diseases, comprising administering an effective
amount of a compound according to Formulas I-III or
pharmaceutically acceptable salts thereof.
[0337] The compounds of the present invention can also be used in a
method of treating patients suffering from disease states
characterized by decreased NMDA function, such as schizophrenia.
The compounds can also be used to treat psychosis characterized by
elevated levels of PDE 4, for example, various forms of depression,
such as manic depression, major depression, and depression
associated with psychiatric and neurological disorders.
[0338] The compounds of the present invention can also be used in
methods of treating patients suffering from obesity and in treament
methods for neuronal regeneration or neurogenesis.
[0339] As mentioned, the compounds of the invention also exhibit
anti-inflammatory activity. As a result, the inventive compounds
are useful in the treatment of a variety of allergic and
inflammatory diseases, particularly disease states characterized by
decreased cyclic AMP levels and/or elevated phosphodiesterase 4
levels. Thus, in accordance with a further embodiment of the
invention, there is provided a method of treating allergic and
inflammatory disease states, comprising administering an effective
amount of a compound according to Formulae I-III or a
pharmaceutically acceptable salt thereof. Such disease states
include: asthma, chronic bronchitis, chronic obstructive pulmonary
disease (COPD), atopic dermatitis, urticaria, allergic rhinitis,
allergic conjunctivitis, vernal conjunctivitis, esoniophilic
granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis,
septic shock, ulcerative colitis, Crohn's disease, reperfusion
injury of the myocardium and brain, chronic glomerulonephritis,
endotoxic shock, adult respiratory distress syndrome, cystic
fibrosis, arterial restenosis, artherosclerosis, keratosis,
rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus,
pneumoconiosis, chronic obstructive airways disease, chronic
obstructive pulmonary disease, toxic and allergic contact eczema,
atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis
in the anogenital area, alopecia areata, hypertrophic scars,
discoid lupus erythematosus, systemic lupus erythematosus,
follicular and wide-area pyodermias, endogenous and exogenous acne,
acne rosacea, Beghet's disease, anaphylactoid purpura nephritis,
inflammatory bowel disease, leukemia, multiple sclerosis,
gastrointestinal diseases, autoimmune diseases and the like.
[0340] PDE4 inhibitors for treating asthma, chronic bronchitis,
psoriasis, allergic rhinitis, and other inflammatory diseases, and
for inhibiting tumor necrosis factor are known within the art. See,
e.g., WO 98/58901, JP11-189577, JP 10-072415, WO 93/25517, WO
94/14742, U.S. Pat. No. 5,814,651, and U.S. Pat. No. 5,935,978.
These references also describe assays for determining PDE4
inhibition activity, and methods for synthesizing such compounds.
The entire disclosures of these documents are hereby incorporated
by reference.
[0341] PDE4 inhibitors may be used to prevent or ameliorate
osteoporosis, as an antibiotic, for treatment of cardiovascular
disease by mobilizing cholesterol from atherosclerotic lesions, to
treat rheumatoid arthritis (RA), for long-term inhibition of
mesenchymal-cell proliferation after transplantation, for treatment
of urinary obstruction secondary to benign prostatic hyperplasia,
for suppression of chemotaxis and reduction of invasion of colon
cancer cells, for treatment of B cell chronic lymphocytic leukemia
(B-CLL), for inhibition of uterine contractions, to attenuate
pulmonary vascular ischemia-reperfusion injury (IRI), for corneal
hydration , for inhibition of IL-2R expression and thereby
abolishing HIV-1 DNA nuclear import into memory T cells, for
augmentation of glucose-induced insulin secretion, in both the
prevention and treatment of colitis, and to inhibit mast cell
degranulation.
[0342] The invention is also suitable for use in the treatment of a
class of disorders known as polyglutamine-repeat diseases. These
diseases share a common pathogenic mutation. The expansion of a CAG
repeat, which encodes the amino acid glutamine, within the genome
leads to production of a mutant protein having an expanded
polyglutamine region. For example, Huntington's disease has been
linked to a mutation of the protein huntingtin. In individuals who
do not have Huntington's disease, huntingtin has a polyglutamine
region containing about 8 to 31 glutamine residues. For individuals
who have Huntington's disease, huntingtin has a polyglutamine
region with over 37 glutamine residues. Aside from Huntington's
disease (HD), other known polyglutamine-repeat diseases and the
associated proteins are: dentatorubral-pallidoluysian atrophy,
DRPLA (atrophin-1); spinocerebellar ataxia type-1 (ataxin-1);
spinocerebellar ataxia type-2 (ataxin-2); spinocerebellar ataxia
type-3 also called Machado-Joseph disease, MJD (ataxin-3);
spinocerebellar ataxia type-6 (alpha 1a-voltage dependent calcium
channel); spinocerebellar ataxia type-7 (ataxin-7); and spinal and
bulbar muscular atrophy, SBMA, also know as Kennedy disease
(androgen receptor).
[0343] Thus, in accordance with a further aspect of the invention,
there is provided a method of treating a polyglutamine-repeat
disease or CAG repeat expansion disease comprising administering to
a patient, especially a human, a therapeutically effective amount
of a compound according to Formulas I-III. In accordance with a
further embodiment, there is provided a method of treating
Huntington's disease (HD), dentatorubral-pallidoluysian atrophy
(DRPLA), spinocerebellar ataxia type-1, spinocerebellar ataxia
type-2, spinocerebellar ataxia type-3 (Machado-Joseph disease),
spinocerebellar ataxia type-6, spinocerebellar ataxia type-7, or
spinal and bulbar muscular atrophy, comprising administering to a
patient, especially a human, a therapeutically effective amount of
a compound according to Formulas I-III.
[0344] The compounds of the present invention can be administered
as the sole active agent or in combination with other
pharmaceutical agents such as other agents used in the treatment of
cognitive impairment and/or in the treatment of psychosis, e.g.,
other PDE4 inhibitors, calcium channel blockers, chloinergic drugs,
adenosine receptor modulators, amphakines NMDA-R modulators, mGluR
modulators, and cholinesterase inhibitors (e.g., donepezil,
rivastigimine, and glanthanamine). In such combinations, each
active ingredient can be administered either in accordance with
their usual dosage range or a dose below their usual dosage
range.
[0345] The dosages of the compounds of the present invention depend
upon a variety of factors including the particular syndrome to be
treated, the severity of the symptoms, the route of administration,
the frequency of the dosage interval, the particular compound
utilized, the efficacy, toxicology profile, pharmacokinetic profile
of the compound, and the presence of any deleterious side-effects,
among other considerations.
[0346] The compounds of the invention are typically administered at
dosage levels and in a mammal customary for PDE4 inhibitors such as
those known compounds mentioned above. For example, the compounds
can be administered, in single or multiple doses, by oral
administration at a dosage level of, for example, 0.01-100
mg/kg/day, preferably 0.1-70 mg/kg/day, especially 0.5-10
mg/kg/day. Unit dosage forms can contain, for example, 0.1-50 mg of
active compound. For intravenous administration, the compounds can
be administered, in single or multiple dosages, at a dosage level
of, for example, 0.001-50 mg/kg/day, preferably 0.001-10 mg/kg/day,
especially 0.01-1 mg/kg/day. Unit dosage forms can contain, for
example, 0.1-10 mg of active compound.
[0347] In carrying out the procedures of the present invention it
is of course to be understood that reference to particular buffers,
media, reagents, cells, culture conditions and the like are not
intended to be limiting, but are to be read so as to include all
related materials that one of ordinary skill in the art would
recognize as being of interest or value in the particular context
in which that discussion is presented. For example, it is often
possible to substitute one buffer system or culture medium for
another and still achieve similar, if not identical, results. Those
of skill in the art will have sufficient knowledge of such systems
and methodologies so as to be able, without undue experimentation,
to make such substitutions as will optimally serve their purposes
in using the methods and procedures disclosed herein.
[0348] The present invention will now be further described by way
of the following non-limiting examples. In applying the disclosure
of these examples, it should be kept clearly in mind that other and
different embodiments of the methods disclosed according to the
present invention will no doubt suggest themselves to those of
skill in the relevant art.
[0349] In the foregoing and in the following examples, all
temperatures are set forth uncorrected in degrees Celsius; and,
unless otherwise indicated, all parts and percentages are by
weight.
[0350] The entire disclosures of all applications, patents and
publications, cited above and below, are hereby incorporated by
reference.
EXAMPLE 1
3-Chloromethylpyridine N-Oxide
[0351] Picolyl chloride hydrochloride (8.0 g, 49 mmol) is dissolved
in ice cold, saturated, aqueous sodium bicarbonate (100 mL) and the
mixture is extracted with 2.times.100 mL chloroform. The chloroform
extracts are dried (MgSO.sub.4) and filtered. 32% Peracetic acid in
acetic acid (50 mL) is added to the filtrate and the mixture is
vigorously stirred for 18 h. The mixture is washed twice with cold,
sat., aq. NaHCO.sub.3, dried (MgSO.sub.4), and concentrated in
vacuo. The solid obtained is triturated with hexanes and dried in
vacuo to give 3-chloromethylpyridine N-oxide (2.0 g, 29% yield) as
a white crystalline solid.
[0352] 1H NMR (300 mHz, CDCl.sub.3) .delta. 8.16 (s, 1H), 8.03 (m,
1H), 7.13-7.23 (m, 2H), 4.04 (s, 2H).
The Compounds 2-Chloromethylpyridine N-Oxide and
4-Chloromethylpyridine N-Oxide can be Prepared in a Similar
Manner
EXAMPLE 2
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-
pyridylmethyl)pyridine
[0353] 4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)pyridine (0.28
g, 1.0 mmol) was dissolved in DMF (1 mL) and added drop-wise to a
stirred suspension of NaH (200 mg of a 60% mineral oil dispersion,
5.0 mmol) in DMF (4 mL) at room temperature. After addition was
complete, the mixture was stirred for 0.5 h at room temperature and
3-chloromethylpyridine N-oxide (300 mg, 2.0 mmol) was added in one
portion. The mixture was stirred for 4 h, then carefully quenched
with water and partitioned between EtOAc (50 mL) and water (50 mL).
The EtOAc layer was washed with water (25 mL) and brine (25 mL),
dried (MgSO.sub.4), and concentrated in vacuo. The residue was
purified by flash column chromatography (silica gel) eluting with
30% MeOH in EtOAc to give
4-amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxypyridin-3-ylmethyl)p-
yridine (64 mg, 16% yield).
[0354] 1H NMR (300 mHz, CDCl.sub.3) .delta. 8.16 (m, 3H), 8.08 (d,
1H, J=6.0 Hz), 7.20-7.60 (m, 2H), 6.85 (d, 2H, J=8.5), 6.72 (dd,
1H, J=8.4, 2.4), 6.66 (s, J=2.4 Hz, 2H), 6.40-6.50 (m, 2H), 4.82
(s, 2H), 4.65 (m, 1H), 3.82 (s, 3H), 1.60-1.90 (m, 6H), 1.50-1.60
(m, 2H).
[0355] The following compounds were prepared in a similar fashion
as described above: [0356] a) tert-Butyl
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoate [0357] b) tert-Butyl
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoate [0358] c)
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[2-(2-tet-
rahydropyranyl)-2H-tetrazol-5-yl]aniline [0359] d)
3-Chloro-N-[4-methoxy-3-((3R)-3-tetrahydrofuranyl)oxyphenyl]-N-(1-oxy-3-p-
yridylmethyl)aniline MS (ES): m/z 427 [M+1] [0360] e) tert-Butyl
3-Amino-N-[bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benz-
oate
EXAMPLE 3
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)benz-
oic acid
[0361] A solution consisting of 1.75 g (3.44 mmol) of tert-butyl
4-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoate, 33.5 mL of dichloromethane and 8.4 mL of trifluoroacetic
acid was stirred at room temperature for 5 hours. The solution was
washed with 50 mL of H.sub.2O. Then 50 mL of H.sub.2O was added and
the pH adjusted to 6 by the addition of 10% aqueous NaOH. The
combined aqueous layers were extracted with 2.times.50 mL of
dichloromethane. The combined dichloromethane extracts were
evaporated and the remaining material was purified by flash
chromatography over SiO.sub.2 using 10% MeOH in CH.sub.2Cl.sub.2 as
eluant. The material was triturated with CH.sub.3CN to yield 1.09 g
(73% yield) of the title compound as a tan powder. .sup.1H NMR (300
MHz, CDCl.sub.3) .delta. 8.57 (s, 1H), 8.23 (d, J=6.3 Hz, 1H), 7.72
(d, J=9.0, 2H), 7.4-7.2 (m, 2H), 6.9-6.7 (m, 3H), 6.58 (d, J=9.0,
2H), 4.94 (s, 2H), 4.71 (m, 1H), 3.83 (s, 3H), 2.0-1.7 (m, 6H),
1.7-1.5 (m, 2H). MS (ES): m/z 435 [M+1]
[0362] The following compounds were prepared in a similar manner as
described above: [0363]
3-Amino-N-(3-cyclopentyloxy-4-methoxyphenyl)-N-(1-oxy-3-pyridylmethyl)ben-
zoic acid MS (ES): m/z 435 [M+1] [0364]
3-Amino-N-[bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)benz-
oic acid MS (ES): m/z 453.1 [M+1]
EXAMPLE 4
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-3-(2H-tetraz-
ol-5-yl)aniline
[0365]
N-[Bis-3,4-(difluoromethoxy)phenyl]-N-(1-oxy-3-pyridylmethyl)-4-[2--
(2-tetrahydropyranyl)-2H-tetrazol-5-yl]aniline (1.5 g, 0.26 mmol)
was dissolved in THF (5 mL) and 3 mL of 1N HCl was added. After 6 h
at room temperature, the mixture was neutralized to pH=5 with
saturated aqueous sodium bicarbonate and extracted with EtOAc
(3.times.50 mL). The EtOAc extracts were combined, washed with
brine (50 mL), dried (MgSO.sub.4), and concentrated in vacuo. The
crude residue was loaded onto a RediSep column (10 g, silica gel)
and the product was eluted using a linear gradient from 0% MeOH in
EtOAc to 5% MeOH in EtOAc over 20 min to give 0.96 g of product as
a white powder. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.48 (s,
1H), 8.21 (d, J=6.3 Hz, 1H), 7.77 (m, 2H), 7.50 (d, J=8.0 Hz, 1H),
7.4-7.3 (m, 2H), 7.12 (m, 2H), 6.9-6.8 (m, 2H), 6.51 (t, J=73.6 Hz,
1H), 6.48 (t, J=73.6 Hz, 1H), 5.08 (s, 2H). MS (ES): m/z 477.0
[M+1]
EXAMPLE 5
[0366] In Vitro Measurement of Type 4 Phosphodiesterase Inhibition
Activity
[0367] Human PDE4 was obtained from baculovirus-infected Sf9 cells
that expressed the recombinant enzyme. The cDNA encoding hPDE-4D6
was subcloned into a baculovirus vector. Insect cells (Sf9) were
infected with the baculovirus and cells were cultured until protein
was expressed. The baculovirus-infected cells were lysed and the
lysate was used as source of hPDE-4D6 enzyme. The enzyme was
partially purified using a DEAE ion exchange chromatography. This
procedure can be repeated using cDNA encoding other PDE-4
enzymes.
[0368] Assay:
[0369] Type 4 phosphodiesterases convert cyclic adenosine
monophosphate (cAMP) to 5'-adenosine monophosphate (5'-AMP).
Nucleotidase converts 5'-AMP to adenosine. Therefore the combined
activity of PDE4 and nucleotidase converts cAMP to adenosine.
Adenosine is readily separated from cAMP by neutral alumina columns
Phosphodiesterase inhibitors block the conversion of cAMP to
adenosine in this assay; consequently, PDE4 inhibitors cause a
decrease in adenosine.
[0370] Cell lysates (40 ul) expressing hPDE-4D6 were combined with
50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min
at room temperature. Final concentrations of assay components were:
0.4 ug enzyme, 10 mM Tris-HCl (pH 7.5), 10 mM MgCl.sub.2, 3 uM
cAMP, 0.002 U 5'-nucleotidase, and 3.times.10.sup.4 cpm of
[3H]cAMP. The reaction was stopped by adding 100 .mu.l of boiling 5
mN HCl. An aliquot of 75 .mu.l of reaction mixture was transferred
from each well to alumina columns (Multiplate; Millipore). Labeled
adenosine was eluted into an OptiPlate by spinning at 2000 rpm for
2 min; 150 .mu.l per well of scintillation fluid was added to the
OptiPlate. The plate was sealed, shaken for about 30 min, and cpm
of [.sup.3H]adenosine was determined using a Wallac
Triflux.RTM..
[0371] All test compounds are dissolved in 100% DMSO and diluted
into the assay such that the final concentration of DMSO is 0.1%.
DMSO does not affect enzyme activity at this concentration.
[0372] A decrease in adenosine concentration is indicative of
inhibition of PDE activity. pIC.sub.50 values were determined by
screening 6 to 12 concentrations of compound ranging from 0.1 nM to
10,000 nM and then plotting drug concentration versus
.sup.3H-adenosine concentration. Nonlinear regression software
(Assay Explorer.RTM.) was used to estimate pIC.sub.50 values.
[0373] IC.sub.50 values for the preferred compounds of the
invention are less than 1000 nM, especially less thn 100 nM.
EXAMPLE 6
Method A
[0374] Passive Avoidance in Rats, an in vivo Test for Learning and
Memory
[0375] The test was performed as previously described (Zhang,
H.-T., Crissman, A. M., Dorairaj, N. R., Chandler, L. J., and
O'Donnell, J. M., Neuropsychopharmacology, 2000, 23, 198-204.). The
apparatus (Model E10-16SC, Coulboum Instruments, Allentown, Pa.)
consisted of a two-compartment chamber with an illuminated
compartment connected to a darkened compartment by a guillotine
door. The floor of the darkened compartment consisted of stainless
steel rods through which an electric foot-shock could be delivered
from a constant current source. All experimental groups were first
habituated to the apparatus the day before the start of the
experiment. During the training, the rat (Male Spraque-Dawley
(Harlan) weighing 250 to 350 g) was placed in the illuminated
compartment facing away from the closed guillotine door for 1
minute before the door was raised. The latency for entering the
darkened compartment was recorded. After the rat entered the
darkened compartment, the door was closed and a 0.5 mA electric
shock was administered for 3 seconds. Twenty-four hours later, the
rat was administered 0.1 mg/kg MK-801 or saline, 30 minutes prior
to the injection of saline or test compound (dosed from 0.1 to 2.5
mg/kg, i.p.), which was 30 minutes before the retention test
started. The rat was again placed in the illuminated compartment
with the guillotine door open. The latency for entering the
darkened compartment was recorded for up to 180 seconds, at which
time the trial was terminated.
[0376] All data were analyzed by analyses of variance (ANOVA);
individual comparisons were made using Kewman-Keuls tests. Naive
rats required less than 30 seconds, on average, to cross from the
illuminated compartment to the darkened compartment. However, 24
hours after the electric shock exposure, most rats pretreated with
vehicle did not re-enter the darkened compartment; the average
latency was increased up to 175 seconds (p<0.001). Pretreatment
with MK-801 (0.1 mg/kg) markedly reduced this latency when compared
to the vehicle (p<0.001). This amnesic effect of MK-801 is
reversed in a statistically significant manner by actual test
compounds in a dose-dependent fashion.
EXAMPLE 6
Method B
[0377] Radial Arm Maze Task in Rats, an in vivo Test for Learning
and Memory
[0378] The test was performed as previously described (Zhang,
H.-T., Crissman, A. M., Dorairaj, N. R., Chandler, L. J., and
O'Donnell, J. M., Neuropsychopharmacology, 2000, 23, 198-204.).
Five days after initial housing, rats (male Spraque-Dawley (Harlan)
weighing 250 to 350 g) were placed in the eight-arm radial maze
(each arm was 60.times.10.times.12 cm high; the maze was elevated
70 cm above the floor) for acclimation for two days. Rats were then
placed individually in the center of the maze for 5 minutes with
food pellets placed close to the food wells, and then, the next
day, in the wells at the end of the arms; 2 sessions a day were
conducted. Next, four randomly selected arms were then baited with
one pellet of food each. The rat was restricted to the center
platform (26 cm in diameter) for 15 seconds and then allowed to
move freely throughout the maze until it collected all pellets of
food or 10 minutes passed, whichever came first. Four parameters
were recorded: 1) working memory errors, i.e., entries into baited
arms that had already been visited during the same trial; 2)
reference memory errors, i.e., entries into unbaited arms; 3) total
arm entries; and 4) the test duration (seconds), i.e., the time
spent in the collection of all the pellets in the maze. If the
working memory error was zero and the average reference memory
error was less than one in five successive trials, the rats began
the drug tests. MK-801 or saline was injected 15 minutes prior to
vehicle or test agent, which was given 45 minutes before the test.
Experiments were performed in a lighted room, which contained
several extra-maze visual cues.
[0379] All data were analyzed by analyses of variance (ANOVA);
individual comparisons were made using Kewman-Keuls tests. Compared
to control, MK-801 (0.1 mg/kg, i.p.) increased the frequencies of
both working and reference memory errors (p<0.01). This amnesic
effect of MK-801 on working memory is reversed in a statistically
significant manner by the administration of actual test compounds
in a dose-dependent fashion.
[0380] The preceding examples can be repeated with similar success
by substituting the generically or specifically described reactants
and/or operating conditions of this invention for those used in the
preceding examples.
[0381] While the invention has been illustrated with respect to the
production and of particular compounds, it is apparent that
variations and modifications of the invention can be made without
departing from the spirit or scope of the invention
* * * * *